

**ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ**

**ΔΗΜΗΤΡΙΟΥ Α. ΜΑΥΡΟΥΔΗ**

**ΚΑΘΗΓΗΤΗ**

**ΠΑΘΟΛΟΓΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ**

**ΙΑΤΡΙΚΗΣ ΣΧΟΛΗΣ, ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΚΡΗΤΗΣ**

**ΟΚΤΩΒΡΙΟΣ 2020**

## ΔΗΜΟΓΡΑΦΙΚΑ ΣΤΟΙΧΕΙΑ

Όνοματεπώνυμο:	Δημήτριος Μαυρουδής
Χρόνος και τόπος γέννησης:	1960 - Ηράκλειο Κρήτης
Υπηκοότητα:	Ελληνική
Διεύθυνση κατοικίας:	Δημοκρατίας 27, 71306, Ηράκλειο Κρήτης
Τηλέφωνο – fax:	(2810) 392438 γραφείο 6977461520 κινητό
E-mail:	<a href="mailto:mavrudis@med.uoc.gr">mavrudis@med.uoc.gr</a>
Αρ. δελτίου ταυτότητας:	AZ 456548, Τ.Α. Ηρακλείου 13.8.2007
Άδεια ασκήσεως επαγγέλματος:	Νομαρχία Ηρακλείου, Διεύθυνση Υγιεινής, αριθμός 4603/27.3.1985

## ΠΡΟΫΠΗΡΕΣΙΑ – ΕΚΠΑΙΔΕΥΣΗ

1978 - 1984	Ιατρική Σχολή Πανεπιστημίου Αθηνών
1985 – 1987	Στρατιωτική θητεία στην Πολεμική Αεροπορία Δόκιμος έφεδρος αξιωματικός - ιατρός 126 Σ.Μ.
1987 – 1988	Υπηρεσία υπαίθρου - αγροτικός ιατρός στο Μεταξοχώρι Μονοφατσίου του Νομού Ηρακλείου
1990 – 1992	Ειδίκευση (residency) στην Παθολογία στο νοσοκομείο Hines VA της Ιατρικής Σχολής Loyola στο Ιλλινόις των Η.Π.Α.
1991 – 1992	Επικεφαλής ειδικευομένων (chief resident) στην Παθολογία στο Νοσοκομείο Hines VA της Ιατρικής Σχολής Loyola
1992 – 1995	Εξειδίκευση (fellowship) στην Αιματολογία και Ογκολογία Εθνικό Ινστιτούτο Καρκίνου (NCI)

---

Εθνικό Ινστιτούτο Καρδιάς, Πνευμόνων, Αίματος (NHLBI)

Εθνικά Ινστιτούτα Υγείας (NIH) των Η.Π.Α.

<b>1995 – 1997</b>	Υπεύθυνος ειδικευμένος ιατρός (Attending physician) Μονάδας Μεταμόσχευσης Μυελού των Οστών  Εθνικά Ινστιτούτα Υγείας, Η.Π.Α.
<b>1997 - 2000</b>	Επιστημονικός συνεργάτης Παθολογικής-Ογκολογικής Κλινικής, Πανεπιστημιακού Νοσοκομείου Ηρακλείου
<b>30/3/00 - 31/10/00</b>	Επιμελητής Α' Παθολογίας-Ογκολογίας, Παθολογικής-Ογκολογικής Κλινικής, Πανεπιστημιακού Νοσοκομείου Ηρακλείου
<b>1/11/00 -13/01/04</b>	Επίκουρος Καθηγητής Εργαστηριακής Αιματολογίας Ιατρικής Σχολής, Πανεπιστημίου Κρήτης
<b>13/01/2004 26/05/2011</b>	– Αναπλ. Καθηγητής Παθολογικής Ογκολογίας, Ιατρικής Σχολής, Πανεπιστημίου Κρήτης
<b>26/05/2011 - σήμερα</b>	Καθηγητής Παθολογικής Ογκολογίας, Ιατρικής Σχολής, Πανεπιστημίου Κρήτης
<b>1/6/2014- σήμερα</b>	Διευθυντής Παθολογικής-Ογκολογικής Κλινικής, Πανεπιστημιακού Νοσοκομείου Ηρακλείου

---

## ΤΙΤΛΟΙ ΣΠΟΥΔΩΝ

- 1985 Πτυχίο Ιατρικής Σχολής Πανεπιστημίου Αθηνών
- 1987 Δίπλωμα ECFMG - Διαγωνισμός ιατρικών γνώσεων FMGEMS
- 1990 Εξετάσεις FLEX - άδεια εξασκήσεως ιατρικής στο Ιλλινόις των Η.Π.Α
- 1992 Τίτλος ειδικότητας Παθολογίας στις Η.Π.Α.  
(American Board of Internal Medicine)
- 1995 Τίτλος ειδικότητας Παθολογικής Ογκολογίας στις Η.Π.Α.  
(American Board of Medical Specialties in Medical Oncology)
- 1996 Τίτλος ειδικότητας Αιματολογίας στις Η.Π.Α.  
(American Board of Medical Specialties in Hematology)
- 1996 Τίτλος ειδικότητας Παθολογίας στην Ελλάδα
- 1997 Διδάκτορας της Ιατρικής του Πανεπιστημίου Κρήτης
- 2004 Τίτλος ειδικότητας Παθολογικής Ογκολογίας στην Ελλάδα

## ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΔΗΜΟΣΙΕΥΣΕΙΣ

### Σε διεθνή περιοδικά με σύστημα κριτών

1. Datta AR, Barrett AJ, Jiang YZ, Guimaraes A, **Mavroudis D**, van Rhee F, Gordon AA, Madrigal A. Distinct T cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. *Bone Marrow Transplant* 1994; 14:517-24
2. Lewalle P, Hensel N, Guimaraes A, Couriel D, Jiang YZ, **Mavroudis D**, Barrett AJ. Helper and cytotoxic lymphocyte responses to chronic myeloid leukemia: implications for adoptive immunotherapy with T cells. *Brit J Haematol* 1996; 92:587-94
3. Jiang YZ, Couriel D, **Mavroudis D**, Lewalle P, Malkovska V, Hensel N, Dermime S, Mollrem J, Barrett AJ. Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A. *Immunology* 1996; 87:481-6
4. **Mavroudis D**, Jiang YZ, Hensel N, Lewalle P, Couriel D, Kreitman R, Pastan I, Barrett AJ. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. *Bone Marrow Transplant* 1996; 17:793-9
5. Jiang YZ, **Mavroudis D**, Dermime S, Hensel N, Couriel D, Mollrem J, Barrett AJ. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukemia cells processing and presenting exogenous antigen. *Brit J Haematol* 1996; 93:606-12
6. Mollrem J, Dermime S, Parker K, Jiang YZ, **Mavroudis D**, Hensel N, Fukushima P, Barrett AJ. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. *Blood* 1996; 88:2450-7
7. **Mavroudis D**, Read E, Cottler-Fox M, Couriel D, Mollrem J, Carter C, Yu M, Dunbar C, Barrett J. CD34+ cell dose predicts survival, post transplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. *Blood* 1996; 88:3223-9
8. Jiang YZ, Barrett AJ, Goldman JM, **Mavroudis D**. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. *Ann Hematol* 1997; 74:1-6
9. Jiang YZ, **Mavroudis D**, Dermime S, Mollrem J, Hensel N, Barrett AJ. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-

leukemia effect from graft-versus-host disease. *Bone Marrow Transplant* 1997; 19:899-903

10. Dermime S, **Mavroudis D**, Jiang YZ, Hensel N, Molldrem J, Barrett AJ. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1997; 19:989-99
11. Molldrem J, Clave E, Jiang YZ, **Mavroudis D**, Raptis A, Hensel N, Agarwala V, Barrett AJ. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. *Blood* 1997; 90:2529-34
12. Molldrem J, Caples M, **Mavroudis D**, Plante M, Young N, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. *Brit J Haematol* 1997; 99:699-705
13. **Mavroudis D**, Barrett J. The graft-versus-leukemia effect. *Curr Opin Hematol* 1996; 3:423-9
14. **Mavroudis D**, Read EJ, Molldrem J, Raptis A, Plante M, Carter C, Phang S, Dunbar C, Barrett AJ. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogeneic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. *Bone Marrow Transplant* 1998; 21:431-40
15. Barrett AJ, **Mavroudis D**, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, O'Kunnieff P, Young N, Read EJ. T-cell depleted bone marrow transplantation and delayed T-cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. *Bone Marrow Transplant* 1998; 21:543-51
16. **Mavroudis D**, Dermime S, Molldrem J, Jiang YZ, Raptis A, van Rhee F, Hensel N, Fellowes V, Eliopoulos G, Barrett A.J. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. *Brit J Haematol* 1998; 101:565-70
17. Molldrem J, Jiang YZ, Stetler-Stevenson M, **Mavroudis D**, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. *Brit J Haematol* 1998; 102:1314-22
18. Raptis A, Clave E, **Mavroudis D**, Molldrem J, van Rhee F, Barrett AJ. Polymorphism in CD33 and CD34 genes: a source of minor histocompatibility antigens on haemopoietic progenitor cells? *Brit J Haematol* 1998; 102:1354-8
19. Hensel N, Agarwala V, Jiang YZ, **Mavroudis D**, Molldrem J, Barrett AJ. A

technique for dual determination of cytotoxic and helper lymphocyte precursor frequency by a miniaturized dye release method. *Bone Marrow Transplant* 1999; 23:71-8

20. Kouroussis C, Androulakis N, Kakolyris S, Souglakos J, Kotsakis T, **Mavroudis D**, Katsogridakis K, Vardakis N, Hatzidaki D, Samonis G, Vlachonikolis J, Georgoulis V. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. *J Clin Oncol* 1999; 17:862-9
21. **Mavroudis D**, Malamos N, Alexopoulos A, Kourousis C, Agelaki S, Sarra E, Potamianou A, Kosmas C, Rigatos G, Giannakakis T, Kalbakis K, Apostolaki F, Vlachonikolis J, Kakolyris S, Samonis G, Georgoulis V. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial. *Ann Oncol* 1999; 10:211-5
22. Kouroussis C, Xydakis E, Potamianou A, Giannakakis T, Kakolyris S, Agelaki S, Sara E, Malamos N, Alexopoulos A, **Mavroudis D**, Samonis G, Papadouris S, Georgoulis V, Panagos G. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. *Ann Oncol* 1999; 10:547-52
23. Raptis A, **Mavroudis D**, Suffredini A, Molldrem J, Rhee F, Childs R, Phang S, Barrett AJ. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. *Bone Marrow Transplant* 1999; 24:879-83
24. van Rhee F, Jiang YZ, Vigue F, Kirby M, **Mavroudis D**, Hensel NF, Agarwala V, Clave E, Childs R, Raptis A, Sloand E, Carter C, Read EJ, Barrett J. Human G-CSF-mobilized CD34-positive peripheral blood progenitor cells can stimulate allogeneic T-cell responses: implications for graft rejection in mismatched transplantation. *Br J Haematol* 1999; 105:1014-24
25. **Mavroudis D**, Kourousis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Samonis G, Georgoulis V. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report. *Semin Oncol* 2000; 27(1 Suppl 2):25-30
26. Giannakakis T, Ziras N, Kakolyris S, **Mavroudis D**, Androulakis N, Agelaki S, Parashos M, Sarra E, Dimou T, Hatzidaki D, Vlachonikolis J, Georgoulis V. Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study. *Eur J Cancer* 2000; 36:742-7
27. Kakolyris S, Kouroussis C, Kalbakis K, **Mavroudis D**, Souglakos J, Vardakis N, Kremos S, Georgoulis V. Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin. *Ann Oncol* 2000;

11:757-60

28. **Mavroudis D**, Kourousis C, Androulakis N, Kalbakis K, Agelaki S, Kakolyris S, Souglakos J, Sarra E, Vardakis N, Hatzidaki D, Samonis G, Georgoulis V. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. *Am J Clin Oncol* 2000; 23:341-4
29. **Mavroudis D**, Alexopoulos A, Ziras N, Malamos N, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Tsavaris N, Potamianou A, Rigatos G, Georgoulis V. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. *Ann Oncol* 2000; 11:1249-54
30. Kakolyris S, Souglakos J, Agelaki S, Kourousis C, **Mavroudis D**, Sarra E, Malliotakis P, Georgoulis V. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy. *Lung Cancer* 2000; 30:193-8
31. Kouroussis C, Agelaki S, **Mavroudis D**, Souglakos J, Kakolyris S, Kalbakis K, Vardakis N, Reppa D, Hatzidaki D, Samonis G, Georgoulis V. A dose escalation study of weekly docetaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2000; 46:488-92
32. Stathopoulos GP, **Mavroudis D**, Tsavaris N, Kouroussis C, Aravantinos G, Agelaki S, Kakolyris S, Rigatos S, Karabekios S, Georgoulis V. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for pancreatic cancer. *Ann Oncol* 2001; 12:101-3
33. Kakolyris S, **Mavroudis D**, Tsavaris N, Souglakos J, Tsiadaki P, Kalbakis K, Agelaki S, Androulakis N, Georgoulis V. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC). A multicenter phase II study. *Ann Oncol* 2001; 12:193-7
34. Kakolyris S, Souglakos J, Kouroussis C, Androulakis N, **Mavroudis D**, Kalbakis K, Kotsakis A, Vardakis N, Koukourakis M, Romanos J, Georgoulis V. A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer. *Oncology* 2001; 60:207-13
35. **Mavroudis D**, Papadakis E, Veslemes M, Tsiadaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonikolis J, Georgoulis V. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first line treatment in patients with small cell lung cancer. *Ann Oncol* 2001; 12:463-70
36. Samonis G, Anatoliotaki M, Apostolakou H, Maraki S, **Mavroudis D**, Georgoulis V. Transient fungemia due to *Rhodotorula rubra* in a cancer patient: case report and review of the literature. *Infection* 2001; 29:173-6



37. Kouroussis C, Souglakos J, Kakolyris S, **Mavroudis D**, Malamos N, Kalbakis K, Androulakis N, Agelaki A, Vardakis N, Samonis G, Georgoulas V. Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: A phase II study. *Oncology* 2001; 61:36-41
38. Kouroussis C, Kakolyris S, **Mavroudis D**, Androulakis N, Kalbakis K, Agelaki S, Sarra E, Souglakos J, Christodoulakis M, Samonis G, Georgoulas V. A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors. *Am J Clin Oncol* 2001; 24:404-7
39. Alexopoulos A, Kouroussis C, Malamos N, Kakolyris S, Kalbakis K, Kosmas C, **Mavroudis D**, Agelaki S, Vlachonikolis J, Sarra E, Rigatos G, Georgoulas V. Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front line chemotherapy in metastatic breast cancer: a multicenter phase II study. *Ann Oncol* 2001; 12:793-8
40. Kalbakis K, Kouroussis C, Kakolyris S, **Mavroudis D**, Souglakos J, Agelaki S, Vamvakas L, Christodoulakis M, Stylianos K, Georgoulas V. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with anthracycline and taxane refractory metastatic breast cancer (MBC). *Brit J Cancer* 2001; 85:798-802
41. Agelaki S, Kakolyris S, Palamidas P, Rigatos G, Kouroussis C, **Mavroudis D**, Kalbakis K, Hatzidaki D, Georgoulas V, Raptis A. A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small cell lung cancer. *Lung Cancer* 2001; 34:133-9
42. Kakolyris S, Kouroussis C, Souglakos J, **Mavroudis D**, Agelaki S, Kalbakis K, Androulakis N, Vardakis N, Vamvakas L, Georgoulas V. A phase I clinical trial of topotecan given every two weeks in patients with refractory solid tumors. *Oncology* 2001; 61:265-70
43. Georgoulas V, Samonis G, Papadakis E, Alexopoulos A, Tsiadaki X, Rapti A, Veslemes M, Grigoratou T, Palamidas P, Kouroussis C, **Mavroudis D**, Kakolyris S, Giannakakis T, Vlachonikolis J. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. *Lung Cancer* 2001; 34 Suppl 4:S47-51
44. **Mavroudis D**. New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV] *Rev Pneumol Clin*. 2001 Nov;57(5 Pt 2):S42-5. Review
45. Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, **Mavroudis D**, Ziras N, Androulakis N, Kalbakis K, Sarra E, Souglakos J, Georgoulas V. Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: A multicenter phase II study. *Am J Clin Oncol* 2002; 25:65-70

46. Kosmas C, Agelaki S, Giannakakis T, **Mavroudis D**, Kouroussis Ch, Kalbakis K, Papadouris S, Souglakos J, Malamos N, Georgoulas V. Phase I study of vinorelbine and Carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer. *Oncology* 2002; 62:103-9
47. Kakolyris S, Kouroussis C, Koukourakis M, **Mavroudis D**, Malas K, Vardakis N, Bozionelou V, Kalbakis K, Georgoulas V. A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors. *Oncology* 2002; 63:213-8
48. Lydaki E, Nikoloudi E, Bolonaki E, **Mavroudis D**, Kandidaki E. Altering interface detector positioning in combination with prestorage filtration to achieve a better quality of single donor platelet concentrates using the CS 3000 Plus blood separator. *J Clin Apheresis* 2002; 17:21-6
49. Souglakos J, **Mavroudis D**, Kakolyris S, Kourousis C, Vardakis N, Androulakis N, Agelaki S, Kalbakis K, Tsetis D, Athanasiadis N, Samonis G, Georgoulas V. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. *J Clin Oncol* 2002; 20:2651-7
50. **Mavroudis D**, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Georgoulas V. Phase I study of paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) administered every two weeks in patients with advanced solid tumors. *Oncology* 2002, 62:216-22
51. Kakolyris S, Kouroussis C, Koukourakis M, Kalbakis K, **Mavroudis D**, Vardakis N, Georgoulas V. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. *Anticancer Res* 2002; 22:1891-6
52. Stathopoulou A, Vlachonikolis I, **Mavroudis D**, Perraki M, Kouroussis Ch, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulas V. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. *J Clin Oncol* 2002; 20:3404-12
53. Souglakos J, Kotsakis A, Kouroussis C, Kakolyris S, **Mavroudis D**, Kalbakis K, Agelaki S, Vlachonikolis J, Georgoulas V, Samonis G. Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors. *Cancer* 2002; 95:1326-33
54. **Mavroudis D**, Veslemes M, Kouroussis C, Tzanakis N, Ferdoutsis E, Toubis M, Ziotopoulos P, Agelidou M, Tselepatiotis E, Kalbakis K, Souglakos J, Magkanas E, Samonis G, Georgoulas V. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. *Lung Cancer* 2002; 38:59-63

55. Androulakis N, Kouroussis C, **Mavroudis D**, Kakolyris S, Souglakos J, Agelaki S, Kalbakis K, Malas K, Pallis A, Samonis G, Georgoulas V. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumors. *Eur J Cancer* 2002; 38:1992-7
56. Solomon SR, Tran T, Carter CS, Donnelly S, Hensel N, Schindler J, Bahceci E, Chetie V, Michalek J, **Mavroudis D**, Read EJ, Vitetta ES, Barrett AJ. Optimized clinical-scale culture conditions for ex-vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. *Cytotherapy* 2002; 4:395-406
57. Kouroussis C, Souglakos J, **Mavroudis D**, Papadouris S, Kakolyris S, Agelaki S, Kalbakis K, Panopoulos C, Vardakis N, Sarra E, Georgoulas V. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer. *Am J Clin Oncol* 2002; 25:627-3
58. **Mavroudis D**, Pavlaku G, Blazoyiannakis G, Veslemes M, Apostolopoulou F, Kouroussis Ch, Kakolyris S, Agelaki S, Androulakis N, Vardakis N, Magkanas E, Samonis G, Georgoulas V. Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. *Lung Cancer* 2003; 39:71-6
59. **Mavroudis D**, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Nikolaidou M, Samonis G, Marselos M, Georgoulas V. A dose escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. *Ann Oncol* 2003; 14:304-12
60. Kouroussis C, Agelaki S, **Mavroudis D**, Kakolyris S, Androulakis N, Kalbakis K, Souglakos J, Mallas K, Bozionelou V, Pallis A, Adamtziki H, Georgoulas V. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. *Anticancer Res* 2003; 23:785-91
61. **Mavroudis D**, Alexopoulos A, Malamos N, Ardavanis A, Kandyli C, Stavrinidis E, Kouroussis Ch, Agelaki S, Androulakis N, Bozionelou V, Georgoulas V. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial. *Oncology* 2003; 64:207-12
62. Stathopoulou A, **Mavroudis D**, Perraki M, Apostolaki S, Vlachonikolis J, Lianidou E, Georgoulas V. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. *Anticancer Res* 2003; 23:1883-90
63. Xenidis N, Vlachonikolis I, **Mavroudis D**, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, Lianidou E, Georgoulas V. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable

breast cancer. *Ann Oncol* 2003; 14: 849-55

64. Pallis A, **Mavroudis D**, Androulakis N, Souglakos J, Kouroussis C, Bozionelou V, Vlachonikolis I, Georgoulas V. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. *Lung Cancer* 2003; 40: 301-7
65. Souglakos J, Androulakis N, **Mavroudis D**, Kouroussis C, Kakolyris S, Vardakis N, Kalbakis K, Pallis A, Ardavanis A, Varveris C, Georgoulas V. A multicenter dose finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. *Int J Radiat Oncol* 2003; 56: 1284-7
66. Dimitriou H, Vorgia P, Stiakaki E, **Mavroudis D**, Markaki E, Koumantakis E, Kalmanti M. In vitro proliferative and differentiating characteristics of CD133<sup>+</sup> and CD34<sup>+</sup> cord blood cells in the presence of Thrombopoietin (TPO) or Erythropoietin (EPO). Potential implications for hematopoietic cell transplantation. *Leukemia Res* 2003; 27: 1143-51
67. Fountzilias G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, **Mavroudis D**, Gogas H, Georgoulas V, Skarlos D. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. *Clin Breast Cancer*. 2003; 4: 120-5
68. Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, **Mavroudis D**, Georgoulas V, Lianidou ES. Real-time quantification of CK-19 mRNA positive cells in peripheral blood of breast cancer patients using the LightCycler system. *Clin Cancer Res*, 2003; 9:5145-51
69. Samonis G, Maraki S, Kouroussis C, **Mavroudis D**, Georgoulas V. Salmonella enterica pneumonia in a patient with lung cancer. *J Clin Microbiol*. 2003; 41:5820-2
70. Giatromanolaki A, Koukourakis MI, Kakolyris S, **Mavroudis D**, Kouroussis C, Mavroudi C, Perraki M, Sivridis E, Georgoulas V. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. *Int J Cancer*. 2004; 108:620-7
71. Anatoliotaki M, Valatas V, Mantadakis E, Apostolakou H, **Mavroudis D**, Georgoulas V, Rolston KV, Kontoyiannis DP, Galanakis E, Samonis G. Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. *Infection*. 2004; 32:65-71
72. Kouroussis C, **Mavroudis D**, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos

- J, Agelaki S, Malas K, Bozionelou V, Georgoulas V. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. *Lung Cancer* 2004; 44:363-8
73. Kakolyris S, Souglakos J, Kouroussis C, Androulakis N, Samonis G, Vardakis N, Amarantidis K, Agelaki S, **Mavroudis D**, Xenidis N, Georgoulas V. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. *Oncology* 2004; 66:253-9.
74. **Mavroudis D**, Malamos N, Polyzos A, Kouroussis Ch, Christophilakis Ch, Varthalitis I, Androulakis N, Kalbakis K, Milaki G, Georgoulas V. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. *Oncology* 2004;67:250-6
75. Bozionellou V, **Mavroudis D**, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulas V. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. *Clin Cancer Res.* 2004; 10:8185-94
76. Stathopoulos EN, Sanidas E, Kafousi M, **Mavroudis D**, Askoxylakis J, Bozionelou V, Perraki M, Tsiftsis D, Georgoulas V. Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. *Ann Oncol.* 2005; 16:240-6
77. Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H, Markopoulos C, Linardou H, **Mavroudis D**, Briasoulis E, Pavlidis N, Razis E, Kosmidis P, Gogas H. Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. *Breast Cancer Res Treat.* 2005; 92:1-9
78. Georgoulas V, Agelidou A, Syrigos K, Rapti A, Agelidou M, Nikolakopoulos J, Polyzos A, Athanasiadis A, Tselepatiotis E, Androulakis N, Kalbakis K, Samonis G, **Mavroudis D**. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. *Br J Cancer.* 2005; 93:763-9
79. Souglakos J, Kakolyris S, Vardakis N, Androulakis N, **Mavroudis D**, Vamvakas L, Kouroussis C, Agelaki S, Saridaki Z, Georgoulas V. A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors. *Cancer Invest.* 2005; 23:505-10

80. Souglakos J, Pallis A, Kakolyris S, **Mavroudis D**, Androulakis N, Kouroussis C, Agelaki S, Xenidis N, Milaki G, Georgoulas V. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. *Oncology*. 2005; 69:384-90
81. Ignatiadis M, **Mavroudis D**, Veslemes M, Boukovinas J, Syrigos K, Agelidou M, Agelidou A, Gerogianni A, Pavlaku G, Tselepatiotis E, Nikolakopoulos J, Georgoulas V. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. *Clin Lung Cancer*. 2005; 7:183-9
82. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis C, Vamvakas L, Kalykaki A, Samonis G, **Mavroudis D**, Georgoulas V. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). *Br J Cancer*. 2006; 94:798-805
83. Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, **Mavroudis D**, Malamos N, Georgoulas V, Lianidou ES. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. *Int J Cancer*. 2006; 119:1654-9
84. Ardavanis A, **Mavroudis D**, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S, Georgoulas V; Breast Cancer Committee of the Hellenic Oncology Research Group. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. *Cancer Chemother Pharmacol*. 2006; 58:742-8
85. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulas V, **Mavroudis D**. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. *J Clin Oncol*. 2006; 24:3756-62
86. Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, **Mavroudis D**, Georgoulas V. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. *Breast Cancer Res*. 2006; 8:R36

87. Hatzidaki D, Agelaki S, **Mavroudis D**, Vlachonikolis I, Alegakis A, Georgoulas V; Lung Cancer Group of the Hellenic Oncology Research Group. A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer. *Clin Lung Cancer*. 2006; 8:49-55
88. Ntoulia M, Kaklamanis L, Valavanis C, Kafousi M, Stathopoulos E, Arapantoni P, **Mavroudis D**, Georgoulas V, Lianidou ES. HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. *Clin Biochem*. 2006; 39:942-6
89. Ntoulia M, Stathopoulou A, Ignatiadis M, Malamos N, **Mavroudis D**, Georgoulas V, Lianidou ES. Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. *Clin Biochem*. 2006; 39:879-8
90. Boukovinas I, Androulakis N, Vamvakas L, Papakotoulas P, Ziras N, Polyzos A, Kalykaki A, Kotsakis A, Xenidis N, Gioulmbasanis I, **Mavroudis D**, Georgoulas V. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group. *Ann Oncol*. 2006; 17:1687-92
91. Petrikkos GL, Skiada A, Samonis G, **Mavroudis D**, Daikos GL. Native valve Aspergillus endocarditis in two patients with aplastic anaemia. *Scand J Infect Dis*. 2006; 38:916-20
92. **Mavroudis D**, Bolonakis I, Cornet S, Myllaki G, Kanellou P, Kotsakis A, Galanis A, Nikoloudi I, Spyropoulou M, Menez J, Miconnet I, Niniraki M, Cordopatis P, Kosmatopoulos K, Georgoulas V. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. *Oncology*. 2006; 70:306-14
93. Kakolyris S, Kalbakis K, Potamianou A, Malamos N, Vamvakas L, Christophillakis C, Tselepatiotis E, Giassas S, **Mavroudis D**, Amarantidis K, Georgoulas V. Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study. *Oncology*. 2006; 70:273-9
94. Pallis AG, Christofillakis Ch, Tselepatiotis E, Agelaki S, Vamvakas L, Souglakos J, Vardakis N, Kalykaki A, Kotsakis A, Argiraki A, **Mavroudis D**, Georgoulas V. Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: A multicenter phase II trial. *Lung Cancer*. 2007; 55:101-7

95. Pappas P, **Mavroudis D**, Nikolaidou M, Georgoulas V, Marselos M. Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine. *Anticancer Drugs*. 2006; 17:1185-91
96. Souglakos J, Kalykaki A, Vamvakas L, Androulakis N, Kalbakis K, Agelaki S, Vardakis N, Tzardi M, Kotsakis AP, Gioulbasanis J, Tsetis D, Sfakiotaki G, Chatzidaki D, **Mavroudis D**, Georgoulas V. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. *Ann Oncol*. 2006; 18:305-10
97. Repapinou Z, Karababa P, Boussiou M, Kafarakis V, Papadaki HA, **Mavroudis D**, Eliopoulos GD, Loutradi-Anagnostou A. An improved method for the diagnostic approach of alpha(+)-thalassaemia. *Clin Lab Haematol*. 2007; 29:45-51
98. Kouloubinis A, Kaklamanis L, Ziras N, Sofroniadou S, Makaritsis K, Adamopoulos S, Revela I, Athanasiou A, **Mavroudis D**, Georgoulas V. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. *Int J Cardiol*. 2007; 122:195-201
99. Apostolaki S, Perraki M, Pallis A, Bozionellou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulas V, **Mavroudis D**. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. *Ann Oncol*. 2007; 18:851-8
100. Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kouroussis Ch, **Mavroudis D**, Pallis A, Agelaki S, Kalbakis K, Georgoulas V. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial. *J BUON*. 2005; 10:47-52
101. Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kouroussis Ch, **Mavroudis D**, Pallis A, Agelaki S, Kalbakis K, Georgoulas V. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. *Dig Dis*. 2007; 25:100-5
102. Koutsopoulos AV, **Mavroudis D**, Dambaki KI, Souglakos J, Tzortzaki EG, Drositis J, Delides GS, Georgoulas V, Stathopoulos EN. Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. *Lung Cancer*. 2007; 57:193-200



103. Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, Sfakiotaki G, Papadatos-Pastos D, Kalmanti L, Kafousi M, Stathopoulos E, Kakolyris S, **Mavroudis D**, Georgoulis V. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. *Ann Oncol*. 2007; 18:1623-31
104. Kallergi G, **Mavroudis D**, Georgoulis V, Stournaras C. Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. *Mol Med*. 2007 ;13:79-88
105. Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E, Touroutoglou N, Chatzidakis A, Georgoulis V, **Mavroudis D**, Souglakos J. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. *BMC Cancer*. 2007; 7:91
106. Bozionelou V, Vamvakas L, Pappas P, Agelaki S, Androulakis N, Kalykaki A, Nikolaidou M, Kentepozidis N, Giassas S, Marselos M, Georgoulis V, **Mavroudis D**. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. *Br J Cancer*. 2007; 97:43-9
107. Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulis V, **Mavroudis D**. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. *J Clin Oncol*. 2007; 25:2727-34
108. Kotsakis A, Kouroussis Ch, Androulakis N, Agelaki S, Kalbakis K, Vamvakas L, Vardakis N, Kalykaki A, Polyzos A, Georgoulis V, **Mavroudis D**. A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors. *Oncology*. 2006; 71:190-6
109. Kalykaki A, Vamvakas L, Agelaki S, Kalbakis K, Vardakis N, Sfakiotaki G, Ignatiadis M, Saridaki Z, Karabeazis A, **Mavroudis D**, Georgoulis V. dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors. *Oncology*. 2006; 71:197-203
110. Stahtea XN, Roussidis AE, Kanakis I, Tzanakakis GN, Chalkiadakis G, **Mavroudis D**, Kletsas D, Karamanos NK. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. *Int J Cancer*. 2007; 121:2808-14
111. Georgoulis V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinou V, Boukovinas I,

- Geroyianni A, Vamvakas L, **Mavroudis D**. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial. *Lung Cancer*. 2007; 59:57-63
112. Karampeazis A, Vamvakas L, Agelaki S, Kentepozidis N, Papadimitraki E, Gioulbasanis I, Vardakis N, Ignatiadis M, **Mavroudis D**, Georgoulas V. Dose Escalation Study of Biweekly Oral Vinorelbine and Gemcitabine in Patients with Solid Tumors. *Oncology*. 2007; 71:347-53
113. Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulas V, **Mavroudis D**. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. *J Clin Oncol*. 2007; 25:5194-202
114. Kalbakis K, Pappas P, Kouroussis C, Vamvakas L, Kalykaki A, Vardakis N, Nikolaidou M, Marselos M, Georgoulas V, **Mavroudis D**. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2007; 62:449-56
115. Saridaki Z, Bozionelou V, Kentepozidis N, Kotsakis A, Vardakis N, Kalykaki A, Gioulbasanis I, Karabeazis A, Vamvakas L, Georgoulas V, **Mavroudis D**. A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors. *Oncology*. 2007; 72:45-50
116. Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M, Stathopoulos E, **Mavroudis D**, Georgoulas V. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. *Br J Cancer*. 2007; 97:1560-6
117. Papadopoulos S, Kouvatseas G, Skarlos D, Malamos N, Delliou E, Saratsiotou I, Ardavanis A, **Mavroudis D**, Skarpidi E, Arapantoni P, Karyda I, Patakioyta F, Aravantinos G, Razis E, Fountzilas G, Kosmidis P. Comparison of HER2 detection methods between central and regional laboratories in Greece. *Clin Breast Cancer*. 2007; 7:784-90
118. Ignatiadis M, Georgoulas V, **Mavroudis D**. Circulating tumor cells in breast cancer. *Curr Opin Obstet Gynecol*. 2008; 20:55-60
119. Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E, Sotiriou C, Georgoulas V, **Mavroudis D**. Molecular detection and prognostic value of circulating cytokeratin-19

messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. *Clin Breast Cancer*. 2007; 7:883-9

120. Kalykaki A, Papakotoulas P, Tsousis S, Boukovinas I, Kalbakis K, Vamvakas L, Kotsakis A, Vardakis N, Papadopoulou P, Georgoulas V, **Mavroudis D**; Hellenic Oncology Research Group. Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). *Anticancer Res*. 2008; 28:495-500
121. Souglakos J, Boukovinas I, Taron M, Mendez P, **Mavroudis D**, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulas V, Rosell R. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. *Br J Cancer*. 2008; 98:1710-5
122. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulas V, **Mavroudis D**. Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer. *Clin Cancer Res*. 2008; 14:2593-600
123. Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, Papakotoulas P, Agelidou A, Geroyianni A, Agelidou M, Hatzidaki D, **Mavroudis D**, Georgoulas V; Hellenic Oncology Research Group (HORG). Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. *Lung Cancer*. 2008; 62:356-63
124. Boukovinas I, Souglakos J, Hatzidaki D, Kakolyris S, Ziras N, Vamvakas L, Polyzos A, Geroyianni A, Agelidou A, Agelaki S, Kalbakis K, Kotsakis A, **Mavroudis D**, Georgoulas V. Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: A multicenter phase II study. *Lung Cancer*. 2009; 63:77-82
125. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulas V, **Mavroudis D**, Voutsina A. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. *Br J Cancer*. 2008 Sep 16;99(6):923-9
126. Saloustros E, **Mavroudis D**, Georgoulas V. Paclitaxel and docetaxel in the treatment of breast cancer. *Expert Opin Pharmacother*. 2008; 9:2603-16

127. Kallergi G, Agelaki S, Kalykaki A, Stournaras C, **Mavroudis D**, Georgoulas V. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. *Breast Cancer Res.* 2008;10:R80
128. Boukovinas I, Papadaki C, Mendez P, Taron M, **Mavroudis D**, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Stathopoulos E, Georgoulas V, Rosell R, Souglakos J. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. *PLoS ONE.* 2008;3:e3695
129. Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulas V, **Mavroudis D**. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. *Breast Cancer Res Treat.* 2008; 117:525-34
130. Gioulbasanis I, Saridaki Z, Kalykaki A, Vamvakas L, Kalbakis K, Ignatiadis M, Amarantidis K, Kakolyris S, Georgoulas V, **Mavroudis D**. Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial. *Anticancer Res.* 2008; 28:3019-25
131. Ignatiadis M, Georgoulas V, **Mavroudis D**. Micrometastatic disease in breast cancer: clinical implications. *Eur J Cancer.* 2008; 44:2726-36
132. Kioulafa M, Kaklamanis L, Stathopoulos E, **Mavroudis D**, Georgoulas V, Lianidou ES. Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. *Ann Oncol.* 2009; 20:1020-5
133. Bozionelou V, Kalbakis K, Vamvakas L, Agelaki S, Androulakis N, Kalykaki A, Georgoulas V, **Mavroudis D**. A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer. *Cancer Chemother Pharmacol.* 2009; 64:785-91
134. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulas V, **Mavroudis D**, Voutsina A. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. *Br J Cancer.* 2008; 99:923-9
135. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulas V, **Mavroudis D**. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. *J Clin Oncol.* 2009; 27: 2177-84

136. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulas V, **Mavroudis D**. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. *Clin Lung Cancer*. 2009; 10:118-23
137. Valachis A, Mauri D, Polyzos NP, **Mavroudis D**, Georgoulas V, Casazza G. Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials. *Crit Rev Oncol Hematol*. 2009 Apr 13
138. Kioulafa M, Kaklamanis L, **Mavroudis D**, Georgoulas V, Lianidou ES. Prognostic significance of RASSF1A promoter methylation in operable breast cancer. *Clin Biochem*. 2009; 42:970-5
139. Saridaki Z, Pappas P, Souglakos J, Nikolaidou M, Vardakis N, Kotsakis A, Marselos M, Georgoulas V, **Mavroudis D**. A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2009; 65:121-8
140. Papadaki C, **Mavroudis D**, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E, Georgoulas V, Souglakos J. Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. *Clin Cancer Res*. 2009; 15:3827-33
141. Agelaki S, Spiliotaki M, Markomanolaki H, Kallergi G, **Mavroudis D**, Georgoulas V, Stournaras C. Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. *Cancer Biol Ther*. 2009; 8:1470-7
142. Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, **Mavroudis D**, Georgoulas V, Lianidou ES. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. *Int J Cancer*. 2009; 125:2887-92
143. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, **Mavroudis D**, Georgoulas V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. *Cancer Lett*. 2010 Feb 1;288(1):99-106. Epub 2009 Jul 19
144. Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, Kontopodis E, Hatzidaki D, **Mavroudis D**, Georgoulas V. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow

of patients with operable breast cancer. *Br J Cancer*. 2009; 101:589-97

145. Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulas V, **Mavroudis D**. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). *Breast Cancer Res Treat*. 2009 Jul 28.
146. Gialeli Ch, Kletsas D, **Mavroudis D**, Kalofonos HP, Tzanakakis GN, Karamanos NK. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. *Curr Med Chem*. 2009; 16:3797-804
147. Saloustros E, Zaganas I, Mavridis M, Vamvakas L, Plaitakis A, Georgoulas V, **Mavroudis D**. Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma. *J Neurooncol*. 2010 Apr;97(2):291-4. Epub 2009 Oct 2
148. Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, Stathopoulos E, **Mavroudis D**, Georgoulas V, Voutsina A. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. *Lung Cancer*. 2010 Jul;69(1):110-5. Epub 2009 Oct 24
149. Saloustros E, Androulakis N, Vamvakas L, **Mavroudis D**, Georgoulas V. Favorable clinical course of patients experiencing bevacizumab-induced proteinuria. *Case Rep Oncol*. 2010 Oct 12;3(3):368-71
150. **Mavroudis D**, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N, Georgoulas V; on behalf of the Breast Cancer Investigators of the Hellenic Oncology Research Group. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. *Ann Oncol*. 2010 Jan;21(1):48-54. Epub 2009 Nov 11
151. Kallergi G, Markomanolaki H, Giannoukarakaki V, Papadaki MA, Strati A, Lianidou E, Georgoulas V, **Mavroudis D**, Agelaki S. Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. *Breast Cancer Res*. 2009;11(6):R84. Epub 2009 Nov 17
152. Valachis A, Polyzos NP, Georgoulas V, **Mavroudis D**, Mauri D. Lack of

evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis. *Gynecol Oncol.* 2010 Apr;117(1):139-45. Epub 2010 Jan 12. Review

153. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulas V, **Mavroudis D**, Mauri D. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. *Breast Cancer Res Treat.* 2010 Jul;122(1):1-7. Epub 2010 Jan 9. Review
154. Saloustros E, **Mavroudis D**. Cytokeratin-19 positive circulating tumor cells in early breast cancer prognosis. *Future Oncology* in press
155. Saloustros E, **Mavroudis D**. Letter to the Editor for article by Esserman L, Shieh Y, Thompson I. Rethinking Screening for Breast Cancer and Prostate Cancer. *JAMA.* 2009; 302(15):1685-1692
156. Mauri D, Valachis A, Polyzos NP, Tsali L, **Mavroudis D**, Georgoulas V, Casazza G. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. *J Natl Compr Canc Netw.* 2010 Mar;8(3):279-86
157. Valachis A, Mauri D, Polyzos NP, **Mavroudis D**, Georgoulas V, Casazza G. Partial breast irradiation or whole breast radiotherapy for early breast cancer: a meta-analysis of randomized controlled trials. *Breast J.* 2010 May-Jun;16(3):245-51
158. Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, Kalbakis K, Vamvakas L, **Mavroudis D**, Georgoulas V. Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. *Cancer Chemother Pharmacol.* 2010 Apr 29
159. Saridaki Z, Papadatos-Pastos D, Tzardi M, **Mavroudis D**, Bairaktari E, Arvanity H, Stathopoulos E, Georgoulas V, Souglakos J. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. *Br J Cancer.* 2010 Jun 8;102(12):1762-8
160. Karachaliou N, Saloustros E, Vamvakas L, **Mavroudis D**, Georgoulas V. Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer. *Ann Oncol.* 2010 Aug;21(8):1729-30
161. Baka S, Agelaki S, Kotsakis A, Veslemes M, Papakotoulas P, Agelidou M, Agelidou A, Tsaroucha E, Pavlaku G, Gerogianni A, Androulakis N, Vamvakas L, Kalbakis K, **Mavroudis D**, Georgoulas V. Phase III study

comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer. *Anticancer Res.* 2010 Jul;30(7):3031-8

162. Lianidou ES, **Mavroudis D**, Sotiropoulou G, Agelaki S, Pantel K. What's new on circulating tumor cells? A meeting report. *Breast Cancer Res.* 2010;12(4):307
163. Polyzos A, Kalbakis K, Kentepozidis N, Giassas S, Kalykaki A, Vardakis N, Bozionelou V, Saloustros E, Kontopodis E, Georgoulas V, **Mavroudis D**. Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab. *Cancer Chemother Pharmacol.* 2010 Oct 5
164. Gioulbasanis I, Baracos VE, Giannousi Z, Xyrafas A, Martin L, Georgoulas V, **Mavroudis D**. Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history. *Ann Oncol.* 2010 Oct 11
165. **Mavroudis D**. Circulating cancer cells. *Ann Oncol.* 2010 Oct;21 Suppl 7:vii95-vii100
166. Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, **Mavroudis D**, Georgoulas V. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. *Cancer Chemother Pharmacol.* 2010 Nov 11
167. Vardakis N, Messaritakis I, Papadaki C, Agoglossakis G, Sfakianaki M, Saridaki Z, Apostolaki S, Koutroubakis I, Perraki M, Hatzidaki D, **Mavroudis D**, Georgoulas V, Souglakos J. Prognostic Significance of the Detection of Peripheral Blood CEACAM5mRNA-Positive Cells by Real Time Polymerase Chain Reaction in Operable Colorectal Cancer. *Clin Cancer Res.* 2011 Jan 1;17(1):165-73
168. Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, **Mavroudis D**, Stathopoulos E, Georgoulas V, Souglakos J. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced / metastatic non-small-cell lung cancer. *Br J Cancer.* 2010 Dec 14
169. Spiliotaki M, Markomanolaki H, Mela M, **Mavroudis D**, Georgoulas V, Agelaki S. Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. *Lung Cancer.* 2010 Dec 27
170. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki



E, Trypaki M, Messaritakis I, Stathopoulos E, **Mavroudis D**, Georgoulas V, Souglakos J. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in  $\geq 2$  line cetuximab-based therapy of colorectal cancer patients. *PLoS One*. 2011 Jan 20;6(1):e15980

171. Daskalakis M, **Mavroudis D**, Sanidas E, Apostolaki S, Askoxylakis I, de Bree E, Georgoulas V, Melissas J. Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection. *Eur J Surg Oncol*. 2011 May;37(5):404-10
172. Pallis AG, Karampeazis A, Vamvakas L, Vardakis N, Kotsakis A, Bozionelou V, Kalykaki A, Hatzidaki D, **Mavroudis D**, Georgoulas V. Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group. *Ann Oncol*. 2011 Nov;22(11):2448-55. Epub 2011 Mar 10
173. Saridaki Z, Malamos N, Kourakos P, Polyzos A, Ardavanis A, Androulakis N, Kalbakis K, Vamvakas L, Georgoulas V, **Mavroudis D**. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. *Cancer Chemother Pharmacol*. 2012 Jan;69(1):35-42. Epub 2011 May 18
174. Gioulbasanis I, Georgoulas P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, Papandreou CN, **Mavroudis D**, Georgoulas V. Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: Interrelations and associations with prognosis. *Lung Cancer*. 2011;74:516-20
175. Kallergi G, Papadaki MA, Politaki E, **Mavroudis D**, Georgoulas V, Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. *Breast Cancer Res*. 2011;13:R59
176. Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A, Georgoulas V, **Mavroudis D**. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. *Breast Cancer Res*. 2011;13:R60
177. Boukovinas I, Androulakis N, Kentepozidis N, Polyzos A, Papakotoulas P, Ziras N, Kotsakis A, Vardakis N, Karampeazis A, Markos V, Kostakopoulos A, Constantinides CA, Samonis G, **Mavroudis D**, Georgoulas V. Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic

Oncology Research Group(HORG). *Cancer Chemother Pharmacol*. 2012 Feb;69(2):351-6. Epub 2011 Jul 12

178. Saloustros E, Kalbakis K, Vardakis N, Kalykaki A, Milaki G, Rovithi M, Agelaki S, Saridaki Z, Georgoulas V, **Mavroudis D**. Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer. *J BUON*. 2011;16:215-8
179. Valachis A, Mauri D, Polyzos NP, Chlouverakis G, **Mavroudis D**, Georgoulas V. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis. *Breast*. 2011 Dec;20(6):485-90. Epub 2011 Jul 23. Review
180. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet*. 2011 Aug 27;378(9793):771-84. Epub 2011 Jul 28.
181. Vetsika EK, Konsolakis G, Aggouraki D, Kotsakis A, Papadimitraki E, Christou S, Menez-Jamet J, Kosmatopoulos K, Georgoulas V, **Mavroudis D**. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. *Cancer Immunol Immunother*. 2012 Feb;61(2):157-68. Epub 2011 Aug 20
182. Kotsakis A, Vetsika EK, Christou S, Hatzidaki D, Vardakis N, Aggouraki D, Konsolakis G, Georgoulas V, Christophyllakis C, Cordopatis P, Kosmatopoulos K, **Mavroudis D**. Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase(TERT) peptide: results of an expanded phase II study. *Ann Oncol*. 2012 Feb;23(2):442-9. Epub 2011 Aug 25
183. Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulas V, **Mavroudis D**. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. *Ann Oncol*. 2012 May;23(5):1164-9. doi: 10.1093/annonc/mdr405. Epub 2011 Sep 21.
184. Giannousi Z, Gioulbasanis I, Pallis AG, Xyrfas A, Dalliani D, Kalbakis K, Papadopoulos V, **Mavroudis D**, Georgoulas V, Papandreou CN. Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis. *Support Care Cancer*. 2012 Aug;20(8):1823-9. doi: 10.1007/s00520-011-1282-x. Epub 2011 Oct 1.
185. Strati A, Markou A, Parisi C, Politaki E, **Mavroudis D**, Georgoulas V,

- Lianidou E. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. *BMC Cancer*. 2011;11:422
186. Vetsika EK, Papadimitraki E, Aggouraki D, Konsolakis G, Mela ME, Kotsakis A, Christou S, Patramani S, Alefantinou M, Kaskara A, Christophyllakis C, Kosmatopoulos K, Georgoulas V, **Mavroudis D**. Sequential Administration of the Native TERT572 Cryptic Peptide Enhances the Immune Response Initiated by its Optimized Variant TERT572Y in Cancer Patients. *J Immunother*. 2011;34:641-50
  187. Saloustros E, **Mavroudis D**. Case 17-2011: a woman with a mass in the breast and overlying skin changes. *N Engl J Med*. 2011;365:1259-60
  188. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. *Lancet*. 2011 Nov 12;378(9804):1707-16. Epub 2011 Oct 19. Review.
  189. Gioulbasanis I, Patrikidou A, Kitikidou K, Papadimitriou K, Vlachostergios PJ, Tsatsanis C, Margioris AN, Papandreou CN, **Mavroudis D**, Georgoulas V. Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosis. *Nutr Cancer*. 2012;64(1):41-7. Epub 2011 Nov 18
  190. Jacquín JP, Jones S, Magné N, Chapelle C, Ellis P, Janni W, **Mavroudis D**, Martín M, Laporte S. Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. *Breast Cancer Res Treat*. 2012 Aug;134(3):903-13.
  191. Karachaliou N, Kouroussis C, Papakotoulas P, Kalbakis K, Tryfonidis K, Vardakis N, Poppis E, Georgoulas V, **Mavroudis D**. A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. *Cancer Chemother Pharmacol*. 2012 May;69(5):1345-52.
  192. Georgoulas V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Xyrafas A, **Mavroudis D**. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK19 mRNA-positive circulating tumor cells: results of a randomized phase II study. *Ann Oncol*. 2012 Jul;23(7):1744-50.

193. Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, **Mavroudis D**, Stathopoulos E, Georgoulas V, Souglakos J. ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer. *J Thorac Oncol*. 2012 Apr;7(4):663-71
194. Saloustros E, **Mavroudis D**. CTCs in Primary Breast Cancer (II). *Recent Results Cancer Res*. 2012;195:187-92.
195. Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, Pallis A, Kalbakis K, Xyrafas A, **Mavroudis D**, Georgoulas V. Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer. *Br J Cancer*. 2012 Jun 5;106(12):1917-25.
196. Karachaliou N, Ziras N, Syrigos K, Tryfonidis K, Papadimitraki E, Kontopodis E, Bozionelou V, Kalykaki A, Georgoulas V, **Mavroudis D**. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. *Cancer Chemother Pharmacol*. 2012 Jul;70(1):169-76.
197. Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, **Mavroudis D**, Georgoulas V. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. *Mod Pathol*. 2013 Feb;26(2):302-13.
198. Laliotis A, Vrekoussis T, Kafousi M, Sanidas E, Askoxilakis J, Melissas J, **Mavroudis D**, Castanas E, Stathopoulos EN. Immunohistochemical study of pElk-1 expression in human breast cancer: Association with breast cancer biologic profile and clinicopathologic features. *Breast*. 2013 Feb;22(1):89-95.
199. Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, **Mavroudis D**, Georgoulas V, Souglakos J. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. *Br J Cancer*. 2012 Dec 4;107(12):1932-7.
200. Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N,

- Kalykaki A, Xyrafas A, Kakolyris S, **Mavroudis D**, Georgoulas V. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. *Br J Cancer*. 2013 Feb 19;108(3):549-56.
201. Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, **Mavroudis D**, Georgoulas V. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study. *Cancer*. 2013 Aug 1;119(15):2754-64.
202. Lianidou ES, **Mavroudis D**, Georgoulas V. Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. *Br J Cancer*. 2013 Jun 25;108(12):2426-32.
203. Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, **Mavroudis D**, Stournaras C, Georgoulas V, Agelaki S. Apoptotic Circulating Tumor Cells (CTCs) in early and metastatic breast cancer patients. *Mol Cancer Ther*. 2013 Sep;12(9):1886-95.
204. Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulas V, **Mavroudis D**. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. *Lung Cancer*. 2013 Nov;82(2):324-9.
205. Karachaliou N, Papadaki C, Lagoudaki E, Trypaki M, Sfakianaki M, Koutsopoulos A, **Mavroudis D**, Stathopoulos E, Georgoulas V, Souglakos J. Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPO-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide. *PLoS One*. 2013 Sep 13;8(9):e74611.
206. Tryfonidis K, Boukovinas I, Xenidis N, Christophyllakis C, Papakotoulas P, Politaki E, Malamos N, Polyzos A, Kakolyris S, Georgoulas V, **Mavroudis D**; Hellenic Oncology Research Group (HORG). A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer. *Breast*. 2013 Dec;22(6):1171-7
207. Lianidou ES, **Mavroudis D**, Pantel K. Advances in circulating tumor cells

(ACTC): from basic research to clinical practice. *Breast Cancer Res.* 2013 Dec 5;15(6):319.

208. Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, **Mavroudis D**, Stathopoulos E, Georgoulas V, Souglakos J. BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients' Outcome. *PLoS One.* 2013 Dec 18;8(12):e84604.
209. Kalykaki A, Agelaki S, Kallergi G, Xyrafas A, **Mavroudis D**, Georgoulas V. Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. *Cancer Chemother Pharmacol.* 2014 Apr;73(4):685-93.
210. Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, **Mavroudis D**, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. *Lancet Oncol.* 2014 Apr;15(4):406-14.
211. EBCTCG (Early Breast Cancer Trialists' Collaborative Group)., McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet.* 2014 Jun 21;383(9935):2127-35
212. Fostira F, Konstantopoulou I, **Mavroudis D**, Tryfonopoulos D, Yannoukakos D, Voutsinas GE. Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases. *Clin Genet.* 2015 Apr;87(4):383-7
213. Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes R, Teufel I, Andergassen U, Apostolaki S, Politaki E, **Mavroudis D**, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz

M, Perez E, Piccart M, Borgen E, Naume B, Jimenez J, Aura C, Zorzino L, Cassatella M, Sandri M, Mostert B, Sleijfer S, Kraan J, Janni W, Fehm T, Rack B, Terstappen L, Repollet M, Pierga JY, Miller C, Sotiriou C, Michiels S, Pantel K. International study on inter-reader variability for circulating tumor cells in breast cancer. *Breast Cancer Res.* 2014 Apr 23;16(2):R43.

214. Tryfonidis K, Kafousi M, Perraki M, Apostolaki S, Agelaki S, Georgoulas V, Stathopoulos E, **Mavroudis D**. Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer. *Clin Breast Cancer.* 2014 Dec;14(6):442-50.
215. Matikas A, Kontopodis E, Nintos G, Bilidas T, Kofteridis DP, Papadaki EZ, Lyraraki E, Kanatsouli K, **Mavroudis D**. A case of herpes simplex-associated encephalitis after brain irradiation for lung cancer metastases. *Anticancer Res.* 2014 Aug;34(8):4411-4.
216. Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, **Mavroudis D**, Georgoulas V. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. *Lung Cancer.* 2014 Oct;86(1):59-66.
217. Kalikaki A, Politaki H, Souglakos J, Apostolaki S, Papadimitraki E, Georgoulia N, Tzardi M, **Mavroudis D**, Georgoulas V, Voutsina A. KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer. *PLoS One.* 2014 Aug 19;9(8):e104902.
218. Papadaki MA, Kallergi G, Zafeiriou Z, Manouras L, Theodoropoulos PA, **Mavroudis D**, Georgoulas V, Agelaki S. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. *BMC Cancer.* 2014 Sep 3;14:651.
219. Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, Tsakalaki E, Voutsina A, Koutsopoulos A, **Mavroudis D**, Georgoulas V, Souglakos J. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer. *Br J Cancer.* 2014 Oct 28;111(9):1757-64.
220. Georgoulas V, Apostolaki S, Bozionelou V, Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A, Xyrafas A, Agelaki S, **Mavroudis D**. Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer. *Cancer Chemother Pharmacol.* 2014

Dec;74(6):1217-25.

221. Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulas V, **Mavroudis D**. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer. *Cancer Chemother Pharmacol*. 2015 Jan;75(1):153-60.
222. Saloustros E, Malamos N, Boukovinas I, Kakolyris S, Kouroussis C, Athanasiadis A, Ziras N, Kentepozidis N, Makrantonakis P, Polyzos A, Christophyllakis C, Georgoulas V, **Mavroudis D**. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG). *Breast Cancer Res Treat*. 2014 Dec;148(3):591-7.
223. Spiliotaki M, **Mavroudis D**, Kapranou K, Markomanolaki H, Kallergi G, Koinis F, Kalbakis K, Georgoulas V, Agelaki S. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. *Breast Cancer Res*. 2014 Nov 29;16(6):485.
224. Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, **Mavroudis D**, Georgoulas V, Kotsakis A. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. *J Immunol Res*. 2014;2014:659294
225. Kalikaki A, Voutsina A, Koutsopoulos A, Papadaki C, Sfakianaki M, Yachnakis E, Xyrafas A, Kotsakis A, Agelaki S, Souglakos J, **Mavroudis D**, Georgoulas V. ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. *Cancer Invest*. 2015 Apr;33(4):107-13.
226. Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, **Mavroudis D**, Georgoulas V. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). *Lung Cancer*. 2015 Apr;88(1):57-62.



227. Matikas A, **Mavroudis D**. Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. *Future Oncol*. 2015;11(6):997-1009.
228. **Mavroudis D**, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulas V; Breast Cancer Investigators of Hellenic Oncology Research Group (HORG), Athens, Greece.. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). *Ann Oncol*. 2015 Jul;26(7):1333-40.
229. Polioudaki H, Agelaki S, Chiotaki R, Politaki E, **Mavroudis D**, Matikas A, Georgoulas V, Theodoropoulos PA. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer. *BMC Cancer*. 2015 May 13;15:399.
230. Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, **Mavroudis D**, Georgoulas V. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. *PLoS One*. 2015 Jun 17;10(6):e0123683.
231. Nikolaou C, Matikas A, Papavasiliopoulou M, **Mavroudis D**, Vamvakas L. Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI. *Case Rep Oncol Med*. 2015;2015:659624.
232. Early Breast Cancer Trialists' Collaborative Group (EBCTCG)., Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet*. 2015 Oct 3;386(10001):1353-61.

233. Early Breast Cancer Trialists' Collaborative Group (EBCTCG)., Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsy P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet*. 2015 Oct 3;386(10001):1341-52.
234. Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, **Mavroudis D**, Georgoulas V. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. *Breast Cancer Res*. 2015 Aug 19;17:113.
235. Bamias A, Peroukidis S, Stamatopoulou S, Tzannis K, Koutsoukos K, Andreadis C, Bozionelou V, Pistalimatziou N, Papatsoris A, Stravodimos K, Varthalitis I, Karamouzis M, Milaki G, Agorastos A, Kentepozidis N, Androulakis N, Bompolaki I, Kalofonos H, **Mavroudis D**, Dimopoulos MA. Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG). *Clin Genitourin Cancer*. 2016 Apr;14(2):e153-9.
236. Kontopodis E, Kotsakis A, Kentepozidis N, Syrigos K, Ziras N, Moutsos M, Filippa G, Mala A, Vamvakas L, **Mavroudis D**, Georgoulas V, Agelaki S. A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. *Cancer Chemother Pharmacol*. 2016 May;77(5):949-56
237. **Mavroudis D**, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I, Athanasiadis A, Kentepozidis N, Ziras N, Katsaounis P, Saloustros E, Georgoulas V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece.. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). *Ann Oncol*. 2016 Oct;27(10):1873-8.

238. Kotsakis A, Matikas A, Koinis F, Kentepozidis N, Varthalitis II, Karavassilis V, Samantas E, Katsaounis P, Dermitzaki EK, Hatzidaki D, **Mavroudis D**, Georgoulas V. A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. *Br J Cancer*. 2016 Sep 27;115(7):784-8.
239. Stratigos M, Matikas A, Voutsina A, **Mavroudis D**, Georgoulas V. Targeting angiogenesis in small cell lung cancer. *Transl Lung Cancer Res*. 2016 Aug;5(4):389-400.
240. **Mavroudis D**. The tAnGo fell short of inspiring the audience. *Lancet Oncol*. 2017 May 4. pii: S1470-2045(17)30311-X.
241. **Mavroudis D**, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulas V. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group. *Br J Cancer*. 2017 Jul 11;117(2):164-170.
242. Matikas A, Voutsina A, Lagoudaki E, Hatzidaki D, Trypaki M, Stoupis G, Tzardi M, **Mavroudis D**, Georgoulas V. Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. *Transl Oncol*. 2017 Aug;10(4):693-698.
243. Spiliotaki M, **Mavroudis D**, Kokotsaki M, Vetsika EK, Stoupis I, Matikas A, Kallergi G, Georgoulas V, Agelaki S. Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes. *Mol Oncol*. 2018 Jan;12(1):21-32.
244. Saloustros E, Nikolaou M, Kalbakis K, Polyzos A, Christofillakis C, Kentepozidis N, Pistamaltzian N, Kourousis C, Vamvakas L, Georgoulas V, **Mavroudis D**. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer.

A Multicenter Phase II Trial by the Hellenic Oncology Research Group. Clin Breast Cancer. 2018 Feb;18(1):88-94.

245. Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulas V, **Mavroudis D**. A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. Cell Physiol Biochem. 2017;44(2):594-606.
246. Messaritakis I, Stogiannitsi M, Koulouridi A, Sfakianaki M, Voutsina A, Sotiriou A, Athanasakis E, Xynos E, **Mavroudis D**, Tzardi M, Souglakos J. Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer. PLoS One. 2018 Jun 8;13(6):e0197327.
247. Papadaki C, Stratigos M, Markakis G, Spiliotaki M, Mastrostamatis G, Nikolaou C, **Mavroudis D**, Agelaki S. Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. Breast Cancer Res. 2018 Jul 11;20(1):72.
248. Papadaki MA, Stoupis G, Theodoropoulos PA, **Mavroudis D**, Georgoulas V, Agelaki S. Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Mol Cancer Ther. 2018 Nov 6. pii: molcanther.0584.2018.
249. Cazzaniga ME, Ciruelos E, Fabi A, Garcia-Saenz J, Lindman H, Mavroudis D, Schem C, Steger G, Timotheadou E, Zaman K, Torri V; MACBETH Group. Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project. Cancer Chemother Pharmacol. 2018 Nov 20.
250. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane

H, Bolla MK, McGuffog L, Wang Q, Aalfs CM; ABCTB Investigators, Adams M, Adlard J, Agata S, Ahmed S, Ahsan H, Aittomäki K, Al-Ejeh F, Allen J, Ambrosone CB, Amos CI, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Auber B, Auer PL, Ausems MGEM, Azzollini J, Bacot F, Balmaña J, Barile M, Barjhoux L, Barkardottir RB, Barrdahl M, Barnes D, Barrowdale D, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Bernstein L, Bignon YJ, Blazer KR, Blok MJ, Blomqvist C, Blot W, Bobolis K, Boeckx B, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Børresen-Dale AL, Bozsik A, Bradbury AR, Brand JS, Brauch H, Brenner H, Bressac-de Paillerets B, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Brunet J, Brüning T, Burwinkel B, Buys SS, Byun J, Cai Q, Caldés T, Caligo MA, Campbell I, Canzian F, Caron O, Carracedo A, Carter BD, Castelao JE, Castera L, Caux-Moncoutier V, Chan SB, Chang-Claude J, Chanock SJ, Chen X, Cheng TD, Chiquette J, Christiansen H, Claes KBM, Clarke CL, Conner T, Conroy DM, Cook J, Cordina-Duverger E, Cornelissen S, Coupier I, Cox A, Cox DG, Cross SS, Cuk K, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, Davidson R, De Leeneer K, Devilee P, Dicks E, Diez O, Ding YC, Ditsch N, Doheny KF, Domchek SM, Dorfling CM, Dörk T, Dos-Santos-Silva I, Dubois S, Dugué PA, Dumont M, Dunning AM, Durcan L, Dwek M, Dworniczak B, Eccles D, Eeles R, Ehrencrona H, Eilber U, Ejlersen B, Ekici AB, Eliassen AH; EMBRACE, Engel C, Eriksson M, Fachal L, Faivre L, Fasching PA, Faust U, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gaddam P, Gammon MD, Ganz PA, Gapstur SM, Garber J, Garcia-Barberan V, García-Sáenz JA, Gaudet MM, Gauthier-Villars M, Gehrige A; GEMO Study Collaborators, Georgoulas V, Gerdes AM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goodfellow P, Greene MH, Alnæs GIG, Grip M, Gronwald J, Grundy A, Gschwantler-Kaulich D, Guénel P, Guo Q, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hallberg E, Hamann U, Hamel N, Hankinson S, Hansen TVO, Harrington P, Hart SN, Hartikainen JM, Healey CS; HEBON, Hein A, Helbig S, Henderson A, Heyworth J, Hicks B, Hillemanns P, Hodgson S, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover B, Hopper JL, Hu C, Huang G, Hulick PJ, Humphreys K, Hunter DJ, Ilyanitov EN, Isaacs C, Iwasaki M, Izatt L, Jakubowska A, James P, Janavicius R, Janni W, Jensen UB, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kast K; kConFab/AOCS Investigators, Keeman R, Kerin MJ, Kets CM, Keupers M, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Konstantopoulou I, Kosma VM, Kristensen VN, Kruse TA, Kwong A, Lænkholm AV, Laitman Y, Lalloo F, Lambrechts D, Landsman K, Lasset C, Lazaro C, Le Marchand L, Lecarpentier J, Lee A, Lee E, Lee JW, Lee MH, Lejbkowitz F, Lesueur F, Li J, Lilyquist J, Lincoln A, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Loud JT, Lubinski J, Luccarini C, Lush M, Maclinnis RJ, Maishman T, Makalic E, Kostovska IM, Malone KE, Manoukian S, Manson JE, Margolin S, Martens JWM, Martinez ME, Matsuo K, **Mavroudis D**, Mazoyer S, McLean C, Meijers-Heijboer H, Menéndez P, Meyer J, Miao H, Miller A, Miller N, Mitchell G, Montagna M, Muir K, Mulligan AM, Mulot C, Nadesan S, Nathanson KL; NBSC Collaborators, Neuhausen SL, Nevanlinna H, Nevelsteen I, Niederacher D,

Nielsen SF, Nordestgaard BG, Norman A, Nussbaum RL, Olah E, Olopade OI, Olson JE, Olswold C, Ong KR, Oosterwijk JC, Orr N, Osorio A, Pankratz VS, Papi L, Park-Simon TW, Paulsson-Karlsson Y, Lloyd R, Pedersen IS, Peissel B, Peixoto A, Perez JIA, Peterlongo P, Peto J, Pfeiler G, Phelan CM, Pinchev M, Plaseska-Karanfilska D, Poppe B, Porteous ME, Prentice R, Presneau N, Prokofieva D, Pugh E, Pujana MA, Pylkäs K, Rack B, Radice P, Rahman N, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rennert HS, Rhenius V, Rhiem K, Richardson A, Rodriguez GC, Romero A, Romm J, Rookus MA, Rudolph A, Ruediger T, Saloustros E, Sanders J, Sandler DP, Sangrajang S, Sawyer EJ, Schmidt DF, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seal S, Senter L, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng X, Shimelis H, Shrubsole MJ, Shu XO, Side LE, Singer CF, Sohn C, Southey MC, Spinelli JJ, Spurdle AB, Stegmaier C, Stoppa-Lyonnet D, Sukiennicki G, Surowy H, Sutter C, Swerdlow A, Szabo CI, Tamimi RM, Tan YY, Taylor JA, Tejada MI, Tengström M, Teo SH, Terry MB, Tessier DC, Teulé A, Thöne K, Thull DL, Tibiletti MG, Tihomirova L, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Tong L, Torres D, Tranchant M, Truong T, Tucker K, Tung N, Tyrer J, Ulmer HU, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van Rensburg EJ, Varesco L, Varon-Mateeva R, Vega A, Viel A, Vijai J, Vincent D, Vollenweider J, Walker L, Wang Z, Wang-Gohrke S, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wesseling J, Whittemore AS, Wijnen JT, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yang XR, Yannoukakos D, Zaffaroni D, Zheng W, Zhu B, Ziogas A, Ziv E, Zorn KK, Gago-Dominguez M, Mannermaa A, Olsson H, Teixeira MR, Stone J, Offit K, Ottini L, Park SK, Thomassen M, Hall P, Meindl A, Schmutzler RK, Droit A, Bader GD, Pharoah PDP, Couch FJ, Easton DF, Kraft P, Chenevix-Trench G, García-Closas M, Schmidt MK, Antoniou AC, Simard J. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nat Genet.* 2017 Dec;49(12):1767-1778.

251. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman R, Eilber U, French JD, Qing Chen X, Fachal L, McCue K, McCart Reed AE, Ghoussaini M, Carroll JS, Jiang X, Finucane H, Adams M, Adank MA, Ahsan H, Aittomäki K, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Arun B, Auer PL, Bacot F, Barrdahl M, Baynes C, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Brinton L, Broberg P, Brock IW, Broeks A, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Butterbach K, Cai Q, Cai H, Caldés T, Canzian F, Carracedo A, Carter BD, Castela JE, Chan TL, David Cheng TY, Seng Chia K, Choi JY, Christiansen H, Clarke CL; NBCS Collaborators, Collée M, Conroy DM, Cordina-Duverger E, Cornelissen S, Cox DG, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-

Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Elvira M, Engel C, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gaborieau V, Gabrielson M, Gago-Dominguez M, Gao YT, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulas V, Giles GG, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hamel N, Hankinson S, Harrington P, Hart SN, Hartikainen JM, Hartman M, Hein A, Heyworth J, Hicks B, Hillemanns P, Ho DN, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Hou MF, Hsiung CN, Huang G, Humphreys K, Ishiguro J, Ito H, Iwasaki M, Iwata H, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kasuga Y, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Kosma VM, Kristensen VN, Krüger U, Kwong A, Lambrechts D, Le Marchand L, Lee E, Lee MH, Lee JW, Neng Lee C, Lejbkovicz F, Li J, Lilyquist J, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Lophatananon A, Lubinski J, Luccarini C, Lux MP, Ma ESK, Maclnnis RJ, Maishman T, Makalic E, Malone KE, Kostovska IM, Mannermaa A, Manoukian S, Manson JE, Margolin S, Mariapun S, Martinez ME, Matsuo K, **Mavroudis D**, McKay J, McLean C, Meijers-Heijboer H, Meindl A, Menéndez P, Menon U, Meyer J, Miao H, Miller N, Taib NAM, Muir K, Mulligan AM, Mulot C, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Noh DY, Nordestgaard BG, Norman A, Olopade OI, Olson JE, Olsson H, Olswold C, Orr N, Pankratz VS, Park SK, Park-Simon TW, Lloyd R, Perez JIA, Peterlongo P, Peto J, Phillips KA, Pinchev M, Plaseska-Karanfilska D, Prentice R, Presneau N, Prokofyeva D, Pugh E, Pylkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Ruddy KJ, Rüdiger T, Rudolph A, Ruebner M, Rutgers EJT, Saloustros E, Sandler DP, Sangrajang S, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Scott RJ, Scott C, Seal S, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng G, Sherman ME, Shrubsole MJ, Shu XO, Smeets A, Sohn C, Southey MC, Spinelli JJ, Stegmaier C, Stewart-Brown S, Stone J, Stram DO, Surowy H, Swerdlow A, Tamimi R, Taylor JA, Tengström M, Teo SH, Beth Terry M, Tessier DC, Thanasitthichai S, Thöne K, Tollenaar RAEM, Tomlinson I, Tong L, Torres D, Truong T, Tseng CC, Tsugane S, Ulmer HU, Ursin G, Untch M, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van der Kolk L, van der Luijt RB, Vincent D, Vollenweider J, Waisfisz Q, Wang-Gohrke S, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yamaji T, Yang XR, Har Yip C, Yoo KY, Yu JC, Zheng W, Zheng Y, Zhu B, Ziogas A, Ziv E; ABCTB Investigators; ConFab/AOCS Investigators, Lakhani SR, Antoniou AC, Droit A, Andrulis IL, Amos CI, Couch FJ, Pharoah PDP, Chang-Claude J, Hall P, Hunter DJ, Milne RL, García-Closas M, Schmidt MK, Chanock SJ, Dunning AM, Edwards SL, Bader GD, Chenevix-Trench G, SimNature. 2017 Nov 2;551(7678):92-94.

252. Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, Bolla MK, Shu XO, Lu Y, Cai Q, Al-Ejeh F, Rozali E, Wang Q, Dennis J, Li B, Zeng C, Feng H, Gusev A, Barfield RT, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Barrdahl M, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Brinton L, Broberg P, Brucker SY, Burwinkel B, Caldés T, Canzian F, Carter BD, Castelao JE, Chang-Claude J, Chen X, Cheng TD, Christiansen H, Clarke CL; NBCS Collaborators, Collée M, Cornelissen S, Couch FJ, Cox D, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-Santos-Silva I, Dumont M, Dwek M, Eccles DM, Eilber U, Eliassen AH, Engel C, Eriksson M, Fachal L, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Closas M, Gaudet MM, Ghousaini M, Giles GG, Goldberg MS, Goldgar DE, González-Neira A, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hallberg E, Hamann U, Harrington P, Hein A, Hicks B, Hillemanns P, Hollestelle A, Hoover RN, Hopper JL, Huang G, Humphreys K, Hunter DJ, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones ME, Jung A, Kaaks R, Kerin MJ, Khusnutdinova E, Kosma VM, Kristensen VN, Lambrechts D, Le Marchand L, Li J, Lindström S, Lissowska J, Lo WY, Loibl S, Lubinski J, Luccarini C, Lux MP, MacInnis RJ, Maishman T, Kostovska IM, Mannermaa A, Manson JE, Margolin S, **Mavroudis D**, Meijers-Heijboer H, Meindl A, Menon U, Meyer J, Mulligan AM, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Nordestgaard BG, Olopade OI, Olson JE, Olsson H, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prentice R, Presneau N, Pylkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Rudolph A, Saloustros E, Sandler DP, Sawyer EJ, Schmidt MK, Schmutzler RK, Schneeweiss A, Scott RJ, Scott CG, Seal S, Shah M, Shrubsole MJ, Smeets A, Southey MC, Spinelli JJ, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper W, Taylor JA, Terry MB, Tessier DC, Thomas A, Thöne K, Tollenaar RAEM, Torres D, Truong T, Untch M, Vachon C, Van Den Berg D, Vincent D, Waisfisz Q, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett WC, Winqvist R, Wolk A, Xia L, Yang XR, Ziogas A, Ziv E; kConFab/AOCS Investigators, Dunning AM, Pharoah PDP, Simard J, Milne RL, Edwards SL, Kraft P, Easton DF, Chenevix-Trench G, Zheng W. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nat Genet.* 2018 Jul;50(7):968-978.
253. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Auer PL, Auvinen P, Barrdahl M, Beane Freeman LE, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Bremer M, Brenner H, Brentnall A, Brock IW, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Campa D, Carter BD, Castelao JE, Chanock SJ, Chlebowski R, Christiansen H, Clarke CL, Collée JM, Cordina-Duverger E, Cornelissen



S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Försti A, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulas V, Giles GG, Gilyazova IR, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hankinson SE, Harkness EF, Hart SN, He W, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Jakimovska M, Jakubowska A, Janni W, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kaczmarek K, Kataja V, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Knight JA, Ko YD, Kosma VM, Koutros S, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowitz F, Lilyquist J, Lindblom A, Lindström S, Lissowska J, Lo WY, Loibl S, Long J, Lubiński J, Lux MP, MacInnis RJ, Maishman T, Makalic E, Maleva Kostovska I, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Martinez ME, **Mavroudis D**, McLean C, Meindl A, Menon U, Middha P, Miller N, Moreno F, Mulligan AM, Mulot C, Muñoz-Garzon VM, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen SF, Nordestgaard BG, Norman A, Offit K, Olson JE, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Peto J, Pinchev M, Plaseska-Karanfilska D, Polley EC, Prentice R, Presneau N, Prokofyeva D, Purrington K, Pylkäs K, Rack B, Radice P, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Robson M, Romero A, Ruddy KJ, Ruebner M, Saloustros E, Sandler DP, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seynaeve C, Shah M, Sherman ME, Shrubsole MJ, Shu XO, Slager S, Smeets A, Sohn C, Soucy P, Southey MC, Spinelli JJ, Stegmaier C, Stone J, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Truong T, Tzardi M, Ulmer HU, Untch M, Vachon CM, van Veen EM, Vijai J, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zhang Y, Zheng W, Ziogas A; ABCTB Investigators; kConFab/AOCS Investigators; NBCS Collaborators, Dunning AM, Thompson DJ, Chenevix-Trench G, Chang-Claude J, Schmidt MK, Hall P, Milne RL, Pharoah PDP, Antoniou AC, Chatterjee N, Kraft P, García-Closas M, Simard J, Easton DF. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *Am J Hum Genet.* 2019 Jan 3;104(1):21-34.

254. Polioudaki H, Chantziou A, Kalyvianaki K, Malamos P, Notas G, **Mavroudis D**, Kampa M, Castanas E, Theodoropoulos PA. Nuclear localization of PD-L1: artifact or reality? *Cell Oncol (Dordr).* 2019 Apr;42(2):237-242.

255. Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. *Lancet Oncol.* 2019 Mar;20(3):361-370.
256. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. *Lancet.* 2019 Apr 6;393(10179):1440-1452.
257. Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, **Mavroudis D**, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. *Crit Rev Oncol Hematol.* 2019 Feb;134:39-45.
258. Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Brenner H, Brentnall A, Brinton L, Broberg P, Brock IW, Brucker SY, Burwinkel B, Caldas C, Caldés T, Campa D, Canzian F, Carracedo A, Carter BD, Castela JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Cheng TD, Chin SF, Clarke CL; NBCS Collaborators, Cordina-Duverger E, Couch FJ, Cox DG, Cox A, Cross SS, Czene K, Daly

MB, Devilee P, Dunn JA, Dunning AM, Durcan L, Dwek M, Earl HM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, Gago-Dominguez M, Galle E, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Georgoulas V, Giles GG, Glendon G, Goldgar DE, González-Neira A, Alnæs GIG, Grip M, Guénel P, Haeberle L, HahnenE, Haiman CA, Håkansson N, Hall P, Hamann U, Hankinson S, Harkness EF, Harrington PA, Hart SN, Hartikainen JM, Hein A, Hillemanns P, Hiller L, Holleczeck B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Janni W, John EM, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kabisch M, Kaczmarek K, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kitahara CM, Knight JA, Ko YD, Koppert LB, Kosma VM, Kraft P, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowitz F, Li L, Lindblom A, Lindström S, Linet M, Lissowska J, Lo WY, Loibl S, Lubiński J, Lux MP, MacInnis RJ, Maierthaler M, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, **Mavroudis D**, McLean C, Meindl A, Middha P, Miller N, Milne RL, Moreno F, Mulligan AM, Mulot C, Nassir R, Neuhausen SL, Newman WT, Nielsen SF, Nordestgaard BG, Norman A, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Petridis C, Pinchev M, Prajzendanc K, Prentice R, Presneau N, Prokofieva D, Pylkäs K, Rack B, Radice P, Ramachandran D, Rennert G, Rennert HS, Rhenius V, Romero A, Roycastle R, Saloustros E, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schwentner L, Scott RJ, Scott C, Seynaeve C, Shah M, Simard J, Smeets A, Sohn C, Southey MC, Swerdlow AJ, Talhouk A, Tamimi RM, Tapper WJ, Teixeira MR, Tengström M, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Torres D, Truong T, Turman C, Turnbull C, Ulmer HU, Untch M, Vachon C, van Asperen CJ, van den Ouweland AMW, van Veen EM, Wendt C, Whittemore AS, Willett W, Winqvist R, Wolk A, Yang XR, Zhang Y, Easton DF, Fasching PA, Nevanlinna H, Eccles DM, Pharoah PDP, Schmidt MK. Genome-wide association study of germline variants and breast cancer-specific mortality. *Br J Cancer*. 2019 Mar;120(6):647-657.

259. Papadaki C, Stoupis G, Tsalikis L, Monastiriotti A, Papadaki M, Maliotis N, Stratigos M, Mastrostamatis G, **Mavroudis D**, Agelaki S. Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer. *Oncotarget*. 2019 Jan 29;10(9):966-981.
260. Thomopoulou K, Tzardi M, **Mavroudis D**, Souglakos I A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant

261. Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Alam S, Lagoudaki ED, Messaritakis I, Zoras O, **Mavroudis D**, Georgoulas V, Souglakos J. Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer. *Cancer Res Treat.* 2019 Oct;51(4):1518-1526.
262. Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomäki K, Andrulis IL, Anton-Culver H, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Azzollini J, Balmaña J, Barnes DR, Barrowdale D, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Białkowska K, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Borg A, Brauch H, Brenner H, Broeks A, Burwinkel B, Caldés T, Caligo MA, Campa D, Campbell I, Canzian F, Carter J, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Christiansen H, Chung WK, Claes KBM, Clarke CL; EMBRACE Collaborators; GC-HBOC Study Collaborators; GEMO Study Collaborators, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, de la Hoya M, Dennis J, Devilee P, Diez O, Dörk T, Dunning AM, Dwek M, Eccles DM, Ejlersen B, Ellberg C, Engel C, Eriksson M, Fasching PA, Fletcher O, Flyger H, Friedman E, Frost D, Gabrielson M, Gago-Dominguez M, Ganz PA, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hamann U, He W, Heyworth J, Hogervorst FBL, Hollestelle A, Hoover RN, Hopper JL, Hulick PJ, Humphreys K, Imyanitov EN; ABCTB Investigators; HEBON Investigators; BCFR Investigators, Isaacs C, Jakimovska M, Jakubowska A, James PA, Janavicius R, Jankowitz RC, John EM, Johnson N, Joseph V, Karlan BY, Khusnutdinova E, Kiiski JI, Ko YD, Jones ME, Konstantopoulou I, Kristensen VN, Laitman Y, Lambrechts D, Lazaro C, Leslie G, Lester J, Lesueur F, Lindström S, Long J, Loud JT, Lubiński J, Makalic E, Mannermaa A, Manoochehri M, Margolin S, Maurer T, **Mavroudis D**, McGuffog L, Meindl A, Menon U, Michailidou K, Miller A, Montagna M, Moreno F, Moserle L, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Nevelsteen I, Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade OI, Olsson H, Osorio A, Papp J, Park-Simon TW, Parsons MT, Pedersen IS, Peixoto A, Peterlongo P,

Pharoah PDP, Plaseska-Karanfilska D, Poppe B, Presneau N, Radice P, Rantala J, Rennert G, Risch HA, Saloustros E, Sanden K, Sawyer EJ, Schmidt MK, Schmutzler RK, Sharma P, Shu XO, Simard J, Singer CF, Soucy P, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Swerdlow AJ, Tapper WJ, Taylor JA, Teixeira MR, Terry MB, Teulé A, Thomassen M, Thöne K, Thull DL, Tischkowitz M, Toland AE, Torres D, Truong T, Tung N, Vachon CM, van Asperen CJ, van den Ouweland AMW, van Rensburg EJ, Vega A, Viel A, Wang Q, Wappenschmidt B, Weitzel JN, Wendt C, Winqvist R, Yang XR, Yannoukakos D, Ziogas A, Kraft P, Antoniou AC, Zheng W, Easton DF, Milne RL, Beesley J, Chenevix-Trench G. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nat Commun.* 2019 Apr 15;10(1):1741.

263. Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, Androulakis N, Christopoulou A, Vaslamatzis M, Ardavanis A, Emmanouilides C, Bompolaki I, Kourousis C, Makrantonakis P, Christofyllakis C, Athanasiadis E, Kentepozidis N, Karampeazis A, Katopodi U, Anagnosopoulos A, Papadopoulos G, Prinarakis E, Kalisperi A, **Mavroudis D**, Georgoulis V. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project. *Ann Oncol.* 2019 Aug 1;30(8):1304-1310.
264. Tzanikou E, Markou A, Politaki E, Koutsopoulos A, Psyrris A, **Mavroudis D**, Georgoulis V, Lianidou E. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. *Mol Oncol.* 2019 Dec;13(12):2515-2530.
265. Villaruz LC, Cobo M, Syrigos K, **Mavroudis D**, Zhang W, Kim JS, Socinski MA. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with

stage IV squamous non-small cell lung cancer. *Lung Cancer*. 2019 Oct;136:52-56.

266. Dörk T, Peterlongo P, Mannermaa A, Bolla MK, Wang Q, Dennis J, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Augustinsson A, Freeman LEB, Beckmann MW, Beeghly-Fadiel A, Behrens S, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Burwinkel B, Canzian F, Chan TL, Chang-Claude J, Chanock SJ, Choi JY, Christiansen H, Clarke CL, Couch FJ, Czene K, Daly MB, Dos-Santos-Silva I, Dwek M, Eccles DM, Ekici AB, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, Gao C, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Goldberg MS, Goldgar DE, Guénel P, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Hartman M, Hauke J, Hein A, Hillemanns P, Hogervorst FBL, Hooning MJ, Hopper JL, Howell T, Huo D, Ito H, Iwasaki M, Jakubowska A, Janni W, John EM, Jung A, Kaaks R, Kang D, Kapoor PM, Khusnutdinova E, Kim SW, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kwong A, Lambrechts D, Marchand LL, Li J, Lindström S, Linet M, Lo WY, Long J, Lophatananon A, Lubiński J, Manoochehri M, Manoukian S, Margolin S, Martinez E, Matsuo K, Mavroudis D, Meindl A, Menon U, Milne RL, Mohd Taib NA, Muir K, Mulligan AM, Neuhausen SL, Newman WG, Offit K, Olopade OI, Olshan AF, Olson JE, Olsson H, Park SK, Park-Simon TW, Peto J, Plaseska-Karanfilska D, Pohl-Rescigno E, Presneau N, Rack B, Radice P, Rashid MU, Rennert G, Rennert HS, Romero A, Ruebner M, Saloustros E, Schmidt MK, Schmutzler RK, Schneider MO, Schoemaker MJ, Scott C, Shen CY, Shu XO, Simard J, Slager S, Smichkoska S, Southey MC, Spinelli JJ, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Teo SH, Terry MB, Toland AE, Tollenaar RAEM, Torres D, Torres-Mejía G, Troester MA, Truong T, Tsugane S, Untch M, Vachon CM, Ouweland AMWVD, Veen EMV, Vijai J, Wendt C, Wolk A, Yu JC, Zheng W, Ziogas A, Ziv E; ABCTB Investigators; NBCS Collaborators, Dunning AM, Pharoah PDP, Schindler D, Devilee P, Easton DF. Two truncating variants in FANCC and breast cancer risk. *Sci Rep*. 2019 Aug 29;9(1):12524.

267. Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs CM; ABCTB Investigators, Adank MA, Adlard J, Agata S, Cadoo K, Agnarsson BA, Ahearn T, Aittomäki K, Ambrosone CB, Andrews L, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Arun BK, Asseryanis E, Auber B, Auvinen P, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Beane Freeman LE, Beauparlant CJ, Beckmann MW, Behrens S, Benitez J, Berger R, Bermisheva M, Blanco AM, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Borg A, Brady AF, Brauch H, Brenner H, Brüning T, Burwinkel B, Buys SS, Caldés T, Caliebe A, Caligo MA, Campa D, Campbell IG, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Claes KBM, Clarke CL, Collavoli A, Conner TA, Cox DG, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Ditsch N, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Durda K, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, Foulkes WD, Friebel TM, Friedman E, Gabrielson M, Gaddam P, Gago-Dominguez M, Gao C, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA; GEMO Study Collaborators, Giles GG, Glendon G, Godwin AK, Goldberg

MS, Goldgar DE, Guénel P, Gutierrez-Barrera AM, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hopper JL, Hosgood HD 3rd, Howell A, Hu C, Hulick PJ, Hunter DJ, Imyanitov EN; KConFab, Isaacs C, Jakimovska M, Jakubowska A, James P, Janavicius R, Janni W, John EM, Jones ME, Jung A, Kaaks R, Karlan BY, Khusnutdinova E, Kitahara CM, Konstantopoulou I, Koutros S, Kraft P, Lambrechts D, Lazaro C, Le Marchand L, Lester J, Lesueur F, Lilyquist J, Loud JT, Lu KH, Luben RN, Lubinski J, Mannermaa A, Manoochchri M, Manoukian S, Margolin S, Martens JWM, Maurer T, **Mavroudis D**, Mebirouk N, Meindl A, Menon U, Miller A, Montagna M, Nathanson KL, Neuhausen SL, Newman WG, Nguyen-Dumont T, Nielsen FC, Nielsen S, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Olshan AF, Olson JE, Olsson H, Osorio A, Ottini L, Peissel B, Peixoto A, Peto J, Plaseska-Karanfilska D, Pocza T, Presneau N, Pujana MA, Punie K, Rack B, Rantala J, Rashid MU, Rau-Murthy R, Rennert G, Lejbkowicz F, Rhenius V, Romero A, Rookus MA, Ross EA,

Rossing M, Rudaitis V, Ruebner M, Saloustros E, Sanden K, Santamariña M, Scheuner MT, Schmutzler RK, Schneider M, Scott C, Senter L, Shah M, Sharma P, Shu XO, Simard J, Singer CF, Sohn C, Soucy P, Southey MC, Spinelli JJ, Steele L, Stoppa-Lyonnet D, Tapper WJ, Teixeira MR, Terry MB, Thomassen M, Thompson J, Thull DL, Tischkowitz M, Tollenaar RAEM, Torres D, Troester MA, Truong T, Tung N, Untch M, Vachon CM, van Rensburg EJ, van Veen EM, Vega A, Viel A, Wappenschmidt B, Weitzel JN, Wendt C, Wieme G, Wolk A, Yang XR, Zheng W, Ziogas A, Zorn KK, Dunning AM, Lush M, Wang Q, McGuffog L, Parsons MT, Pharoah PDP, Fostira F, Toland AE, Andrulis IL, Ramus SJ, Swerdlow AJ, Greene MH, Chung WK, Milne RL, Chenevix-Trench G, Dörk T, Schmidt MK, Easton DF, Radice P, Hahnen E, Antoniou AC, Couch FJ, Nevanlinna H, Surrallés J, Peterlongo P. The FANCM:p.Arg658\* truncating variant is associated with risk of triple-negative breast cancer. *NPJ Breast Cancer*. 2019 Nov 1;5:38.

268. Thomopoulou K, Manolakou S, Messaritakis I, Tzardi M, Lagoudaki E, Koutsopoulos A, Koulouris A, Kanellis G, Kalbakis K, **Mavroudis D**, Souglakos I. Brain and bone marrow metastases from rectal cancer. *Ann Gastroenterol*. 2020 Jan-Feb;33(1):95-97.

269. Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, Soucy P, Lemaçon A, Lush M, Tyrer JP, Ghousaini M, Moradi Marjaneh M, Jiang X, Agata S, Aittomäki K, Alonso MR, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Aronson KJ, Arun BK, Auber B, Auer PL, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Beeghly-Fadiel A, Benitez J, Bermisheva M, Białkowska K, Blanco AM, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borg A, Bosse K, Brauch H, Brenner H, Briceno I, Brock IW, Brooks-Wilson A, Brüning T, Burwinkel B, Buys SS, Cai Q, Caldés T, Caligo MA, Camp NJ, Campbell I, Canzian F, Carroll JS, Carter BD, Castelao JE, Chiquette J,



Christiansen H, Chung WK, Claes KBM, Clarke CL; GEMO Study Collaborators; EMBRACE Collaborators, Collée JM, Cornelissen S, Couch FJ, Cox A, Cross SS, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Domchek SM, Dörk T, Dos-Santos-Silva I, Droit A, Dubois S, Dumont M, Duran M, Durcan L, Dwek M, Eccles DM, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Floris G, Flyger H, Foretova L, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gago-Dominguez M, Gambino G, Ganz PA, Gapstur SM, Garber J, García-Sáenz JA, Gaudet MM, Georgoulas V, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Tibiletti MG, Greene MH, Grip M, Gronwald J, Grundy A, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hartikainen JM, Hartman M, He W, Healey CS, Heemskerk-Gerritsen BAM, Heyworth J, Hillemanns P, Hogervorst FBL, Hollestelle A, Hooning MJ, Hopper JL, Howell A, Huang G, Hulick PJ, Imyanitov EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators, Isaacs C, Iwasaki M, Jager A, Jakimovska M, Jakubowska A, James PA, Janavicius R, Jankowitz RC, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kang D, Kapoor PM, Karlan BY, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Kirk J, Kitahara CM, Ko YD, Konstantopoulou I, Kosma VM, Koutros S, Kubelka-Sabit K, Kwong A, Kyriacou K, Laitman Y, Lambrechts D, Lee E, Leslie G, Lester J, Lesueur F, Lindblom A, Lo WY, Long J, Lophatananon A, Loud JT, Lubiński J, MacInnis RJ, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Matsuo K, Maurer T, **Mavroudis D**, Mayes R, McGuffog L, McLean C, Mebirouk N, Meindl A, Miller A, Miller N, Montagna M, Moreno F, Muir K, Mulligan AM, Muñoz-Garzon VM, Muranen TA, Narod SA, Nassir R, Nathanson KL, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nikitina-Zake L, Norman A, Offit K, Olah E, Olopade OI, Olsson H, Orr N, Osorio A, Pankratz VS, Papp J, Park SK, Park-Simon TW, Parsons MT, Paul J, Pedersen IS, Peissel B, Peshkin B, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prajzencanc K, Prentice R, Presneau N, Prokofyeva D, Pujana MA, Pylkäs K, Radice P, Ramus SJ, Rantala J, Rau-Murthy R, Rennert G, Risch HA, Robson M, Romero A, Rossing M, Saloustros E, Sánchez-Herrero E, Sandler DP, Santamariña M, Saunders C, Sawyer EJ, Scheuner MT, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schöttker B, Schürmann P, Scott C, Scott RJ, Senter L, Seynaeve CM, Shah M, Sharma P, Shen CY, Shu XO, Singer CF, Slavin TP, Smichkoska S, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Stoppa-Lyonnet D, Sutter C, Swerdlow AJ, Tamimi RM, Tan YY, Tapper WJ, Taylor JA, Teixeira MR, Tengström M, Teo SH, Terry MB, Teulé A, Thomassen M, Thull DL,

Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Torres D, Torres-Mejía G, Troester MA, Truong T, Tung N, Tzardi M, Ulmer HU, Vachon CM, van Asperen CJ, van der Kolk LE, vanA, Viel A, Vijai J, Vogel MJ, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wildiers H, Winqvist R, Wolk A, Wu AH, Yannoukakos D, Zhang Y, Zheng W, Hunter D, Pharoah PDP, Chang-Claude J, García-Closas M, Schmidt MK, Milne RL, Kristensen VN, French JD, Edwards SL, Antoniou AC, Chenevix-Trench G, Simard J, Easton DF, Kraft P, Dunning AM. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nat Genet.* 2020 Jan;52(1):56-73.

270. Escala-Garcia M, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Ashworth A, Auer PL, Auvinen P, Beckmann MW, Beesley J, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Børresen-Dale AL, Brauch H, Brenner H, Brucker SY, Burwinkel B, Caldas C, Canzian F, Chang-Claude J, Chanock SJ, Chin SF, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Devilee P, Dunn JA, Dunning AM, Dwek M, Earl HM, Eccles DM, Eliassen AH, Ellberg C, Evans DG, Fasching PA, Figueroa J, Flyger H, Gago-Dominguez M, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Giles GG, Goldgar DE, González-Neira A, Grip M, Guénel P, Guo Q, Haiman CA, Håkansson N, Hamann U, Harrington PA, Hiller L, Hoening MJ, Hopper JL, Howell A, Huang CS, Huang G, Hunter DJ, Jakubowska A, John EM, Kaaks R, Kapoor PM, Keeman R, Kitahara CM, Koppert LB, Kraft P, Kristensen VN, Lambrechts D, Le Marchand L, Lejbkowitz F, Lindblom A, Lubiński J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Maurer T, **Mavroudis D**, Meindl A, Milne RL, Mulligan AM, Neuhausen SL, Nevanlinna H, Newman WG, Olshan AF, Olson JE, Olsson H, Orr N, Peterlongo P, Petridis C, Prentice RL, Presneau N, Punie K, Ramachandran D, Rennert G, Romero A, Sachchithananthan M, Saloustros E, Sawyer EJ, Schmutzler RK, Schwentner L, Scott C, Simard J, Sohn C, Southey MC, Swerdlow AJ, Tamimi RM, Tapper WJ, Teixeira MR, Terry MB, Thorne H, Tollenaar RAEM, Tomlinson I, Troester MA, Truong T, Turnbull C, Vachon CM, van der Kolk LE, Wang Q, Winqvist R, Wolk A, Yang XR, Ziogas A, Pharoah PDP, Hall P, Wessels LFA, Chenevix-Trench G, Bader GD, Dörk T, Easton DF, Canisius S, Schmidt MK. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. *Nat Commun.* 2020 Jan 16;11(1):312.

271. Ioannidis G, Papadaki C, Lagoudaki E, Tzardi M, Trypaki M, Stathopoulos E, **Mavroudis D**, Georgoulas V, Souglakos J. Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. *Anticancer Res.* 2020 Feb;40(2):901-913.
272. Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, Androulakis N, Christodoulou C, Kalbakis K, Kalykaki A, Sanidas E, Papadimitriou C, Vamvakas L, Georgoulas V, **Mavroudis D**, Yannoukakos D, Konstantopoulou I, Saloustros E. BRCA1 & BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. *Int J Cancer.* 2020 Feb 5.
273. Papadaki MA, Koutsopoulos AV, Tsoulfas PG, Lagoudaki E, Aggouraki D, Monastirioti A, Koutoulaki C, Apostolopoulou CA, Merodoulaki AC, Papadaki C, **Mavroudis D**, Agelaki S. Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer. *Cancers (Basel).* 2020 Feb 6;12(2).
274. **Mavroudis D**, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulas V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece. Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): *Annals of Oncology*, Volume 26, Issue 7, July 2015, Pages 1333-1340. *Ann Oncol.* 2020 Mar;31(3):444-445

275. Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, Aittomäki K, Andrulis IL, Anton-Culver H, Antoniou AC, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Auer PL, Azzollini J, Balmaña J, Barkardottir RB, Barnes DR, Barrowdale D, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Białkowska K, Blanco A, Blomqvist C, Boeckx B, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borg A, Brauch H, Brenner H, Briceno I, Broeks A, Brüning T, Burwinkel B, Cai Q, Caldés T, Caligo MA, Campbell I, Canisius S, Campa D, Carter BD, Carter J, Castelao JE, Chang-Claude J, Chanock SJ, Christiansen H, Chung WK, Claes KBM, Clarke CL; GEMO Study Collaborators; EMBRACE Collaborators; GC-HBOC study Collaborators, Couch FJ, Cox A, Cross SS, Cybulski C, Czene K, Daly MB, de la Hoya M, De Leener K, Dennis J, Devilee P, Diez O, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Ejlersen B, Ellberg C, Engel C, Eriksson M, Fasching PA, Fletcher O, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gabrielson M, Ganz PA, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hamann U, Hake C, He W, Heyworth J, Hogervorst FBL, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Huang G, Hulick PJ, Humphreys K, Imyanitov EN; ABCTB Investigators; HEBON Investigators; BCFR Investigators; OCGN Investigators, Isaacs C, Jakimovska M, Jakubowska A, James P, Janavicius R, Jankowitz RC, John EM, Johnson N, Joseph V, Jung A, Karlan BY, Khusnutdinova E, Kiiski JI, Konstantopoulou I, Kristensen VN, Laitman Y, Lambrechts D, Lazaro C, Leroux D, Leslie G, Lester J, Lesueur F, Lindor N, Lindström S, Lo WY, Loud JT, Lubiński J, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martens JWM, Martinez ME, Matricardi L, Maurer T, **Mavroudis D**, McGuffog L, Meindl A, Menon U, Michailidou K, Kapoor PM, Miller A, Montagna M, Moreno F, Moserle L, Mulligan AM, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Nevelsteen I, Nielsen FC, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Olsson H, Osorio A, Papp J, Park-Simon TW, Parsons MT, Pedersen IS, Peixoto A, Peterlongo P, Peto J, Pharoah PDP, Phillips KA, Plaseska-Karanfilska D, Poppe B, Pradhan N, Prajzendanc K, Presneau N, Punie K, Pylkäs K, Radice P, Rantala J, Rashid MU, Rennert G, Risch HA, Robson M, Romero A, Saloustros E, Sandler DP, Santos C, Sawyer EJ, Schmidt MK, Schmidt DF, Schmutzler RK, Schoemaker MJ, Scott RJ, Sharma P, Shu XO, Simard J, Singer CF, Skytte AB, Soucy P, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Swerdlow AJ, Tapper WJ, Taylor JA, Teixeira MR, Terry MB, Teulé A, Thomassen M, Thöne K, Thull DL, Tischkowitz M, Toland AE, Tollenaar RAEM, Torres D, Truong T, Tung N, Vachon

CM, van Asperen CJ, van den Ouweland AMW, van Rensburg EJ, Vega A, Viel A, Vieira-Balo P, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Winqvist R, Yang XR, Yannoukakos D, Ziogas A, Milne RL, Easton DF, Chenevix-Trench G, Zheng W, Kraft P, Jiang X. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status *Genet Epidemiol*. 2020 Jul;44(5):442-468

276. Damilakis E, **Mavroudis D**, Sfakianaki M, Souglakos J. Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival? *Cancers (Basel)*. 2020 Apr 6;12(4):889
277. Papadaki C, Manolakou S, Lagoudaki E, Pontikakis S, Ierodiakonou D, Vogiatzoglou K, Messaritakis I, Trypaki M, Giannikaki L, Sfakianaki M, Kalykaki A, **Mavroudis D**, Tzardi M, Souglakos J. Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study. *Cancers (Basel)*. 2020 Apr 6;12(4):889.
278. Messaritakis I, Vogiatzoglou K, Tsantaki K, Ntretaki A, Sfakianaki M, Koulouridi A, Tsiaoussis J, **Mavroudis D**, Souglakos J. The Prognostic Value of the Detection of Microbial Translocation in the Blood of Colorectal Cancer Patients *Cancers (Basel)*. 2020 Apr 24;12(4):1058.
279. Papadaki C, Monastiriotti A, Rounis K, Makrakis D, Kalbakis K, Nikolaou C, **Mavroudis D**, Agelaki S. Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy. *Cancers (Basel)*. 2020 May 19;12(5):1282.

280. Messaritakis I, Koulouridi A, Sfakianaki M, Vogiatzoglou K, Gouvas N, Athanasakis E, Tsiaoussis J, Xynos E, Mavroudis D, Tzardi M, Souglakos J. The Role of Vitamin D Receptor Gene Polymorphisms in Colorectal Cancer Risk. *Cancers (Basel)*. 2020 May 27;12(6):1379.281.Papadaki MA, Sotiriou AI, Vasilopoulou C, Filika M, Aggouraki D, Tsoulfas PG, Apostolopoulou CA, Rounis K, **Mavroudis D**, Agelaki S. Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy. *Cancers (Basel)*. 2020 Jun 12;12(6):1556.
281. Liu J, Prager-van der Smissen WJC, Collée JM, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Augustinsson A, Auvinen P, Becher H, Beckmann MW, Behrens S, Bermisheva M, Bernstein L, Bogdanova NV, Bogdanova-Markov N, Bojesen SE, Brauch H, Brenner H, Briceno I, Brucker SY, Brüning T, Burwinkel B, Cai Q, Cai H, Campa D, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Choi JY, Christiaens M, Clarke CL; NBCS Collaborators, Couch FJ, Czene K, Daly MB, Devilee P, Dos-Santos-Silva I, Dwek M, Eccles DM, Eliassen AH, Fasching PA, Figueroa J, Flyger H, Fritschi L, Gago-Dominguez M, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Goldberg MS, Goldgar DE, Guénel P, Haiman CA, Håkansson N, Hall P, Harrington PA, Hart SN, Hartman M, Hillemanns P, Hopper JL, Hou MF, Hunter DJ, Huo D; ABCTB Investigators, Ito H, Iwasaki M, Jakimovska M, Jakubowska A, John EM, Kaaks R, Kang D, Keeman R, Khusnutdinova E, Kim SW, Kraft P, Kristensen VN, Kurian AW, Le Marchand L, Li J, Lindblom A, Lophatananon A, Luben RN, Lubiński J, Mannermaa A, Manoochchri M, Manoukian S, Margolin S, Mariapun S, Matsuo K, Maurer T, **Mavroudis D**, Meindl A, Menon U, Milne RL, Muir K, Mulligan AM, Neuhausen SL, Nevanlinna H, Offit K, Olopade OI, Olson JE, Olsson H, Orr N, Park SK, Peterlongo P, Peto J, Plaseska-Karanfilska D, Presneau N, Rack B, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Romero A, Ruebner M, Saloustros E, Schmutzler RK, Schneeweiss A, Scott C, Shah M, Shen CY, Shu XO, Simard J, Sohn C, Southey MC, Spinelli JJ, Tamimi RM, Tapper WJ, Teo SH, Terry MB, Torres D, Truong T, Untch M, Vachon CM, van Asperen CJ, Wolk A, Yamaji T, Zheng W, Ziogas A, Ziv E, Torres-Mejía G, Dörk T, Swerdlow

AJ, Hamann U, Schmidt MK, Dunning AM, Pharoah PDP, Easton DF, Hooning MJ, Martens JWM, Hollestelle A. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Sci Rep.* 2020 Jun 16;10(1):9688.

281. Liu J, Prager-van der Smissen WJC, Collée JM, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Augustinsson A, Auvinen P, Becher H, Beckmann MW, Behrens S, Bermisheva M, Bernstein L, Bogdanova NV, Bogdanova-Markov N, Bojesen SE, Brauch H, Brenner H, Briceno I, Brucker SY, Brüning T, Burwinkel B, Cai Q, Cai H, Campa D, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Choi JY, Christiaens M, Clarke CL; NBCS Collaborators, Couch FJ, Czene K, Daly MB, Devilee P, Dos-Santos-Silva I, Dwek M, Eccles DM, Eliassen AH, Fasching PA, Figueroa J, Flyger H, Fritschi L, Gago-Dominguez M, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Goldberg MS, Goldgar DE, Guénel P, Haiman CA, Håkansson N, Hall P, Harrington PA, Hart SN, Hartman M, Hillemanns P, Hopper JL, Hou MF, Hunter DJ, Huo D; ABCTB Investigators, Ito H, Iwasaki M, Jakimovska M, Jakubowska A, John EM, Kaaks R, Kang D, Keeman R, Khusnutdinova E, Kim SW, Kraft P, Kristensen VN, Kurian AW, Le Marchand L, Li J, Lindblom A, Lophatananon A, Luben RN, Lubiński J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Mariapun S, Matsuo K, Maurer T, **Mavroudis D**, Meindl A, Menon U, Milne RL, Muir K, Mulligan AM, Neuhausen SL, Nevanlinna H, Offit K, Olopade OI, Olson JE, Olsson H, Orr N, Park SK, Peterlongo P, Peto J, Plaseska-Karanfilska D, Presneau N, Rack B, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Romero A, Ruebner M, Saloustros E, Schmutzler RK, Schneeweiss A, Scott C, Shah M, Shen CY, Shu XO, Simard J, Sohn C, Southey MC, Spinelli JJ, Tamimi RM, Tapper WJ, Teo SH, Terry MB, Torres D, Truong T, Untch M, Vachon CM, van Asperen CJ, Wolk A, Yamaji T, Zheng W, Ziogas A, Ziv E, Torres-Mejía G, Dörk T, Swerdlow AJ, Hamann U, Schmidt MK, Dunning AM, Pharoah PDP, Easton DF, Hooning MJ, Martens JWM, Hollestelle A. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Sci Rep.* 2020 Jun 16;10(1):9688.

282. Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Manolakou S, Messaritakis I, Saridaki Z, Athanasakis E, **Mavroudis D**, Tsiaoussis J, Gouvas N, Souglakos J. PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer. *Cancers (Basel)*. 2020 Jul 25;12(8):2058.
283. Rojo F, Corassa M, **Mavroudis D**, Öz AB, Biesma B, Brcic L, Pauwels P, Sailer V, Gosney J, Miljkovic D, Hader C, Wu M, Almarez T, Penault-Llorca F. International real-world study of DLL3 expression in patients with small cell lung cancer. *Lung Cancer*. 2020 Sep;147:237-243.
284. Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, **Mavroudis D**, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, De Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein H, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS. Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. *J Natl Cancer Inst*. 2020 Aug 8:djaa113.
285. Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol*. 2020 Sep 21:S1470-2045(20)30541-6.



286. Kramer I, Hoening MJ, Mavaddat N, Hauptmann M, Keeman R, Steyerberg EW, Giardiello D, Antoniou AC, Pharoah PDP, Canisius S, Abu-Ful Z, Andrulis IL, Anton-Culver H, Aronson KJ, Augustinsson A, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Bremer M, Brucker SY, Burwinkel B, Castelao JE, Chan TL, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Choi JY, Clarke CL; NBCS Collaborators, Collée JM, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Evans DG, Fasching PA, Flyger H, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Giles GG, Goldgar DE, González-Neira A, Haiman CA, Håkansson N, Hamann U, Hartman M, Heemskerk-Gerritsen BAM, Hollestelle A, Hopper JL, Hou MF, Howell A; ABCTB Investigators; kConFab Investigators, Ito H, Jakimovska M, Jakubowska A, Janni W, John EM, Jung A, Kang D, Kets CM, Khusnutdinova E, Ko YD, Kristensen VN, Kurian AW, Kwong A, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lubiński J, Mannermaa A, Manoochehri M, Margolin S, Matsuo K, **Mavroudis D**, Meindl A, Milne RL, Mulligan AM, Muranen TA, Neuhausen SL, Nevanlinna H, Newman WG, Olshan AF, Olson JE, Olsson H, Park-Simon TW, Peto J, Petridis C, Plaseska-Karanfilska D, Presneau N, Pylkäs K, Radice P, Rennert G, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmutzler RK, Schwentner L, Scott C, See MH, Shah M, Shen CY, Shu XO, Siesling S, Slager S, Sohn C, Southey MC, Spinelli JJ, Stone J, Tapper WJ, Tengström M, Teo SH, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Vachon CM, van Ongeval C, van Veen EM, Winqvist R, Wolk A, Zheng W, Ziogas A, Easton DF, Hall P, Schmidt MK. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. *Am J Hum Genet.* 2020 Sep 28:S0002-9297(20)30321-9.